NZ758692B2 - Gut-selective sequestering agents for the treatment and prevention of autism and related disorders - Google Patents
Gut-selective sequestering agents for the treatment and prevention of autism and related disordersInfo
- Publication number
- NZ758692B2 NZ758692B2 NZ758692A NZ75869218A NZ758692B2 NZ 758692 B2 NZ758692 B2 NZ 758692B2 NZ 758692 A NZ758692 A NZ 758692A NZ 75869218 A NZ75869218 A NZ 75869218A NZ 758692 B2 NZ758692 B2 NZ 758692B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- sequestrant
- mice
- activated carbon
- administration
- subject
- Prior art date
Links
- 239000003352 sequestering agent Substances 0.000 title claims abstract description 89
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 48
- 206010003805 Autism Diseases 0.000 title description 8
- 208000020706 Autistic disease Diseases 0.000 title description 8
- 230000002265 prevention Effects 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 135
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 113
- 208000029560 autism spectrum disease Diseases 0.000 claims abstract description 57
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 41
- 208000013404 behavioral symptom Diseases 0.000 claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 8
- HXDOZKJGKXYMEW-UHFFFAOYSA-N 4-ethylphenol Chemical group CCC1=CC=C(O)C=C1 HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 claims description 206
- 241000699670 Mus sp. Species 0.000 claims description 136
- 239000002207 metabolite Substances 0.000 claims description 123
- 238000000034 method Methods 0.000 claims description 123
- WGNAKZGUSRVWRH-UHFFFAOYSA-N p-cresol sulfate Chemical compound CC1=CC=C(OS(O)(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-N 0.000 claims description 83
- 230000000968 intestinal effect Effects 0.000 claims description 69
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 68
- 208000024891 symptom Diseases 0.000 claims description 67
- DWZGLEPNCRFCEP-UHFFFAOYSA-N 4-ethylphenyl sulfate Chemical compound CCC1=CC=C(OS(O)(=O)=O)C=C1 DWZGLEPNCRFCEP-UHFFFAOYSA-N 0.000 claims description 50
- 238000002360 preparation method Methods 0.000 claims description 47
- 208000019901 Anxiety disease Diseases 0.000 claims description 44
- 230000006399 behavior Effects 0.000 claims description 35
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 28
- 230000036506 anxiety Effects 0.000 claims description 27
- PCKPVGOLPKLUHR-UHFFFAOYSA-N indoxyl Chemical compound C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 claims description 22
- 210000002700 urine Anatomy 0.000 claims description 21
- 241000736262 Microbiota Species 0.000 claims description 20
- 230000006735 deficit Effects 0.000 claims description 17
- 230000003989 repetitive behavior Effects 0.000 claims description 15
- 206010022998 Irritability Diseases 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 208000013406 repetitive behavior Diseases 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 12
- 238000004891 communication Methods 0.000 claims description 10
- 230000003542 behavioural effect Effects 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 81
- 238000012360 testing method Methods 0.000 description 48
- 239000000463 material Substances 0.000 description 47
- -1 transurocanate Chemical compound 0.000 description 41
- 208000035475 disorder Diseases 0.000 description 35
- 241000699666 Mus <mouse, genus> Species 0.000 description 34
- 230000000813 microbial effect Effects 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 32
- 229920000642 polymer Polymers 0.000 description 32
- 239000011148 porous material Substances 0.000 description 30
- 238000003556 assay Methods 0.000 description 29
- 241000894006 Bacteria Species 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 24
- 239000003053 toxin Substances 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- 210000003608 fece Anatomy 0.000 description 22
- 229920002678 cellulose Polymers 0.000 description 21
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 21
- 229910052753 mercury Inorganic materials 0.000 description 21
- 230000001580 bacterial effect Effects 0.000 description 20
- 239000001913 cellulose Substances 0.000 description 20
- 238000002459 porosimetry Methods 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000000440 bentonite Substances 0.000 description 17
- 229910000278 bentonite Inorganic materials 0.000 description 17
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 17
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 17
- 239000002552 dosage form Substances 0.000 description 17
- 241000606124 Bacteroides fragilis Species 0.000 description 16
- XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 16
- 235000020940 control diet Nutrition 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 229920005989 resin Polymers 0.000 description 16
- 239000011347 resin Substances 0.000 description 16
- 208000025966 Neurological disease Diseases 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000002550 fecal effect Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 208000024827 Alzheimer disease Diseases 0.000 description 13
- 102100030681 SH3 and multiple ankyrin repeat domains protein 3 Human genes 0.000 description 13
- 101710101741 SH3 and multiple ankyrin repeat domains protein 3 Proteins 0.000 description 13
- 229910021536 Zeolite Inorganic materials 0.000 description 13
- 239000003463 adsorbent Substances 0.000 description 13
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 13
- 238000012544 monitoring process Methods 0.000 description 13
- 230000006977 prepulse inhibition Effects 0.000 description 13
- 230000003997 social interaction Effects 0.000 description 13
- 239000010457 zeolite Substances 0.000 description 13
- JHFAEUICJHBVHB-UHFFFAOYSA-N 1h-indol-2-ol Chemical compound C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 description 12
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 12
- 208000009829 Lewy Body Disease Diseases 0.000 description 12
- 201000002832 Lewy body dementia Diseases 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- HBMCQTHGYMTCOF-UHFFFAOYSA-N hydroquinone monoacetate Natural products CC(=O)OC1=CC=C(O)C=C1 HBMCQTHGYMTCOF-UHFFFAOYSA-N 0.000 description 12
- 244000005700 microbiome Species 0.000 description 12
- 231100000765 toxin Toxicity 0.000 description 12
- 108700012359 toxins Proteins 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 208000006289 Rett Syndrome Diseases 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 11
- 210000004558 lewy body Anatomy 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 10
- 229930195725 Mannitol Natural products 0.000 description 10
- 230000004075 alteration Effects 0.000 description 10
- 230000007529 anxiety like behavior Effects 0.000 description 10
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 10
- 235000010355 mannitol Nutrition 0.000 description 10
- 239000000594 mannitol Substances 0.000 description 10
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- 231100000331 toxic Toxicity 0.000 description 10
- 230000002588 toxic effect Effects 0.000 description 10
- 229920001268 Cholestyramine Polymers 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 101150083522 MECP2 gene Proteins 0.000 description 9
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 208000032859 Synucleinopathies Diseases 0.000 description 9
- 229910052586 apatite Inorganic materials 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 9
- 229960000511 lactulose Drugs 0.000 description 9
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 9
- 208000036546 leukodystrophy Diseases 0.000 description 9
- 239000004579 marble Substances 0.000 description 9
- 230000000926 neurological effect Effects 0.000 description 9
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 9
- 201000000980 schizophrenia Diseases 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000002798 spectrophotometry method Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000001755 vocal effect Effects 0.000 description 9
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 8
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 150000008163 sugars Chemical class 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000012085 test solution Substances 0.000 description 8
- 208000009999 tuberous sclerosis Diseases 0.000 description 8
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 7
- 208000027244 Dysbiosis Diseases 0.000 description 7
- 208000001914 Fragile X syndrome Diseases 0.000 description 7
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 7
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 206010049644 Williams syndrome Diseases 0.000 description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 7
- 239000003575 carbonaceous material Substances 0.000 description 7
- 239000004927 clay Substances 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000007140 dysbiosis Effects 0.000 description 7
- 239000003456 ion exchange resin Substances 0.000 description 7
- 229920003303 ion-exchange polymer Polymers 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 6
- RSTKLPZEZYGQPY-UHFFFAOYSA-N 3-(indol-3-yl)pyruvic acid Chemical compound C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1 RSTKLPZEZYGQPY-UHFFFAOYSA-N 0.000 description 6
- FUGYGGDSWSUORM-UHFFFAOYSA-N 4-hydroxystyrene Chemical compound OC1=CC=C(C=C)C=C1 FUGYGGDSWSUORM-UHFFFAOYSA-N 0.000 description 6
- 241000606215 Bacteroides vulgatus Species 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 6
- 241001608234 Faecalibacterium Species 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 241000186604 Lactobacillus reuteri Species 0.000 description 6
- 241000204306 Parabacteroides merdae Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 229940001882 lactobacillus reuteri Drugs 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- XDOFWFNMYJRHEW-UHFFFAOYSA-N m-hydroxyhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(O)=C1 XDOFWFNMYJRHEW-UHFFFAOYSA-N 0.000 description 6
- 230000009919 sequestration Effects 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 5
- 241001464948 Coprococcus Species 0.000 description 5
- 241000186394 Eubacterium Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 240000006024 Lactobacillus plantarum Species 0.000 description 5
- 208000001089 Multiple system atrophy Diseases 0.000 description 5
- 241000604373 Ovatus Species 0.000 description 5
- 241000606210 Parabacteroides distasonis Species 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 241000605861 Prevotella Species 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229920002301 cellulose acetate Polymers 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000021824 exploration behavior Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 238000012346 open field test Methods 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- FVMDYYGIDFPZAX-UHFFFAOYSA-N 3-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=CC(O)=C1 FVMDYYGIDFPZAX-UHFFFAOYSA-N 0.000 description 4
- YHXHKYRQLYQUIH-UHFFFAOYSA-N 4-hydroxymandelic acid Chemical compound OC(=O)C(O)C1=CC=C(O)C=C1 YHXHKYRQLYQUIH-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010063659 Aversion Diseases 0.000 description 4
- 241000606125 Bacteroides Species 0.000 description 4
- 241000217846 Bacteroides caccae Species 0.000 description 4
- 208000027534 Emotional disease Diseases 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- 208000030979 Language Development disease Diseases 0.000 description 4
- 206010034703 Perseveration Diseases 0.000 description 4
- 208000009144 Pure autonomic failure Diseases 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- AVMNFQHJOOYCAP-UHFFFAOYSA-N acetic acid;propanoic acid Chemical compound CC(O)=O.CCC(O)=O AVMNFQHJOOYCAP-UHFFFAOYSA-N 0.000 description 4
- JYIBXUUINYLWLR-UHFFFAOYSA-N aluminum;calcium;potassium;silicon;sodium;trihydrate Chemical compound O.O.O.[Na].[Al].[Si].[K].[Ca] JYIBXUUINYLWLR-UHFFFAOYSA-N 0.000 description 4
- 201000007201 aphasia Diseases 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- 229910001603 clinoptilolite Inorganic materials 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 208000009575 Angelman syndrome Diseases 0.000 description 3
- 206010002869 Anxiety symptoms Diseases 0.000 description 3
- 208000012661 Dyskinesia Diseases 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000028752 abnormal posture Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010228 ex vivo assay Methods 0.000 description 3
- 230000008921 facial expression Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000010439 graphite Substances 0.000 description 3
- 229910002804 graphite Inorganic materials 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001568 phenolic resin Polymers 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- FAGUFWYHJQFNRV-UHFFFAOYSA-N tetraethylenepentamine Chemical compound NCCNCCNCCNCCN FAGUFWYHJQFNRV-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- KXGFMDJXCMQABM-UHFFFAOYSA-N 2-methoxy-6-methylphenol Chemical compound [CH]OC1=CC=CC([CH])=C1O KXGFMDJXCMQABM-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- GTEQEGCHYHVYRO-UHFFFAOYSA-N 4-methyl-5-propylfuran-2,3-dicarboxylic acid Chemical compound C(=O)(O)C1=C(OC(=C1C)CCC)C(=O)O GTEQEGCHYHVYRO-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 206010009696 Clumsiness Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 241000902235 Oides Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920005372 PlexiglasÂź Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N azain Natural products C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007435 diagnostic evaluation Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 2
- 235000019126 equol Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000266 injurious effect Effects 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N methylguanidine Chemical compound CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000005011 phenolic resin Substances 0.000 description 2
- UTYVDVLMYQPLQB-UHFFFAOYSA-N phenylacetylglycine Chemical compound OC(=O)CNC(=O)CC1=CC=CC=C1 UTYVDVLMYQPLQB-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 235000011962 puddings Nutrition 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- QFTLJRFNJYIISH-UHFFFAOYSA-N pyrrolo[2,3-b]pyridine Chemical compound C1=C[N]C2=NC=CC2=C1 QFTLJRFNJYIISH-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000009151 sensory gating Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 230000011273 social behavior Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 238000006277 sulfonation reaction Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229920005992 thermoplastic resin Polymers 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 125000005591 trimellitate group Chemical group 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- 229920003067 (meth)acrylic acid ester copolymer Polymers 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VFOKYTYWXOYPOX-RVDMUPIBSA-N (z)-2,3-diphenylprop-2-enenitrile Chemical compound C=1C=CC=CC=1C(/C#N)=C/C1=CC=CC=C1 VFOKYTYWXOYPOX-RVDMUPIBSA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- HRVRAYIYXRVAPR-UHFFFAOYSA-N 1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound N1C(=O)CCCC2=CC=CC=C21 HRVRAYIYXRVAPR-UHFFFAOYSA-N 0.000 description 1
- AOLNDUQWRUPYGE-UHFFFAOYSA-N 1,4-dioxepan-5-one Chemical compound O=C1CCOCCO1 AOLNDUQWRUPYGE-UHFFFAOYSA-N 0.000 description 1
- PTXVSDKCUJCCLC-UHFFFAOYSA-N 1-hydroxyindole Chemical compound C1=CC=C2N(O)C=CC2=C1 PTXVSDKCUJCCLC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- TVONJMOVBKMLOM-UHFFFAOYSA-N 2-methylidenebutanenitrile Chemical compound CCC(=C)C#N TVONJMOVBKMLOM-UHFFFAOYSA-N 0.000 description 1
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 1
- GOLXRNDWAUTYKT-UHFFFAOYSA-M 3-(1H-indol-3-yl)propanoate Chemical compound C1=CC=C2C(CCC(=O)[O-])=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-M 0.000 description 1
- KHTAGVZHYUZYMF-UHFFFAOYSA-N 3-(3-hydroxyphenyl)-3-hydroxypropanoic acid Chemical compound OC(=O)CC(O)C1=CC=CC(O)=C1 KHTAGVZHYUZYMF-UHFFFAOYSA-N 0.000 description 1
- QVWAEZJXDYOKEH-UHFFFAOYSA-N 3-(3-hydroxyphenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CC(O)=C1 QVWAEZJXDYOKEH-UHFFFAOYSA-N 0.000 description 1
- XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 description 1
- JVQYSWDUAOAHFM-UHFFFAOYSA-M 3-methyl-2-oxovalerate Chemical compound CCC(C)C(=O)C([O-])=O JVQYSWDUAOAHFM-UHFFFAOYSA-M 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 108010089063 4-hydroxybenzoate decarboxylase Proteins 0.000 description 1
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 1
- FBXGQDUVJBKEAJ-UHFFFAOYSA-N 4h-oxazin-3-one Chemical compound O=C1CC=CON1 FBXGQDUVJBKEAJ-UHFFFAOYSA-N 0.000 description 1
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 1
- DUUGKQCEGZLZNO-UHFFFAOYSA-M 5-Hydroxyindoleacetate Chemical compound OC1=CC=C2NC=C(CC([O-])=O)C2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-M 0.000 description 1
- RWHRFHQRVDUPIK-UHFFFAOYSA-N 50867-57-7 Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O RWHRFHQRVDUPIK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 241000282979 Alces alces Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 241001135228 Bacteroides ovatus Species 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 241000283726 Bison Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241001416153 Bos grunniens Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241001058146 Erium Species 0.000 description 1
- 229920003134 EudragitÂź polymer Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000557769 Iodes Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 description 1
- 101100516410 Mus musculus Nts gene Proteins 0.000 description 1
- 206010028403 Mutism Diseases 0.000 description 1
- SNEIUMQYRCDYCH-LURJTMIESA-N N(alpha)-acetyl-L-arginine Chemical compound CC(=O)N[C@H](C(O)=O)CCCNC(N)=N SNEIUMQYRCDYCH-LURJTMIESA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 1
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004236 Ponceau SX Substances 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010039917 Selective mutism Diseases 0.000 description 1
- 208000033712 Self injurious behaviour Diseases 0.000 description 1
- 208000000810 Separation Anxiety Diseases 0.000 description 1
- 239000004113 Sepiolite Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 SokalanÂź Polymers 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229960005488 aceglutamide Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- NPDSHTNEKLQQIJ-ZJHFMPGASA-N alpha-dimorphecolic acid Chemical compound CCCCC\C=C/C=C/C(O)CCCCCCCC(O)=O NPDSHTNEKLQQIJ-ZJHFMPGASA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001268 chyle Anatomy 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- NPDSHTNEKLQQIJ-UHFFFAOYSA-N dimorphecolic acid Natural products CCCCCC=CC=CC(O)CCCCCCCC(O)=O NPDSHTNEKLQQIJ-UHFFFAOYSA-N 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- YEKFYCQGYMVFKR-UHFFFAOYSA-N docosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCC=CC=CC=CC=CC=CC(O)=O YEKFYCQGYMVFKR-UHFFFAOYSA-N 0.000 description 1
- 229940000640 docosahexaenoate Drugs 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- SLGWESQGEUXWJQ-UHFFFAOYSA-N formaldehyde;phenol Chemical compound O=C.OC1=CC=CC=C1 SLGWESQGEUXWJQ-UHFFFAOYSA-N 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- STKYPAFSDFAEPH-LURJTMIESA-N glycylvaline Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000552 p-cresyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1O*)C([H])([H])[H] 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000019355 sepiolite Nutrition 0.000 description 1
- 229910052624 sepiolite Inorganic materials 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 239000002441 uremic toxin Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000011816 wild-type C57Bl6 mouse Methods 0.000 description 1
- FBZONXHGGPHHIY-UHFFFAOYSA-N xanthurenic acid Chemical compound C1=CC=C(O)C2=NC(C(=O)O)=CC(O)=C21 FBZONXHGGPHHIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
The present invention relates to use of an activated carbon sequestrant composition in the manufacture of a medicament for treating a behavioral symptom of a neurological disorder associated with autism spectrum disorder in a subject.
Description
GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS CROSS REFERENCE TO RELATED ATIONS This application claims the benefit of US. Provisional Application Serial No. 62/480,039, filed March 31, 2017, which is hereby expressly incorporated by reference in its entirety.
FIELD The present disclosure relates to methods of treating, inhibiting, or ameliorating a behavioral symptoms of a ogical disorder, such as autism, and ated pathologies including intestinal hyperpermeability or leaky gut.
BACKGROUND Nonâabsorbable, nonâdigestible, biocompatible polymers have been used for lowering cholesterol and systemic phosphate levels by targeting adsorption of cholesterol and free phosphate in the gut. These products are patible ion ge resins that are not absorbed to any significant extent and are excreted from the gastrointestinal (GI) tract after binding their target molecules. For example, the ion exchange resin, cholestyramine, has been used for sequestering bile acids, which are cholesterol derivatives, so as to lower cholesterol. onally, nonâabsorbable, nonâdigestible, biocompatible activated carbon ations have been investigated to counteract the effects of toxins in poisoning and drug overdoses (e.g., Dillon er al. (1989), Ann. Emerg.
Med. 547â52; Kieslichova et al. (2018), Transplantation Proc. 50:192â197), and uremic toxins in the treatment of chronic kidney disease (e.g., Schulman er al. (2016), BMC Nephrology 17:141). For example, an ted carbon particle preparation has been ped and utilized for delaying dialysis in subjects suffering from chronic kidney disease, but the clinical utility of this approach has not been roundly accepted, multiple metaâanalyses have indicated no clear al benefit, and a later stage clinical trial in the US failed to prove efficacy.
SUMMARY In one aspect, the ion provides use of an activated carbon sequestrant composition in the manufacture of a medicament for treating a subject having a behavioral symptom of a ogical disorder associated with autism spectrum disorder in a subject, wherein the ted carbon sequestrant composition is capable of binding to at least a fraction of at least one intestinal metabolite present in the digestive tract of the subject to form a sequestrant-metabolite complex, such that the sequestrant-metabolite complex is ated from the digestive tract; wherein the at least one intestinal metabolite is 4-ethylphenol and the behavioral symptom is selected from the group consisting of repetitive behaviors, stereotyped ors, obsessive behaviors, deficits in social communication, and clinical irritability; wherein the activated carbon sequestrant composition comprises a multiplicity of biocompatible particles which are non-absorbable by the digestive tract of the subject.
In another aspect, the invention provides sequestrant compositions for use in the treatment of a subject having a behavioral symptom of a neurological er associated with intestinal hyperpermeability (or leaky gut) or intestinal dysbiosis. These compositions comprise a licity of biocompatible particles and/or polymers which are gestible and non-absorbable by the digestive tract of the subject. The sequestrant compositions bind to at least a fraction of at least one intestinal metabolite present in the digestive tract of the subject to form a sequestrant-metabolite complex, which may include covalent or non-covalent bonds. As a result of the formation of the sequestrant-metabolite complex, the inal metabolite is eliminated from the digestive tract along with the sequestrant ition, rather than interacting with or being absorbed by the tissues of the digestive tract. The intestinal metabolites which are bound by the sequestrant compositions are associated with the development or presence of the behavioral symptom and, thus, the elimination of the intestinal metabolite aids in the treatment of the behavioral symptom and neurological disorder.
In r aspect, the invention es methods of treating a subject having a behavioral m of a neurological er associated with intestinal hyperpermeability or intestinal dysbiosis. These methods comprise administering to the subject a sequestrant composition of the ion which binds to at least a on of at least one intestinal metabolite present in the digestive tract of the subject. As described above, the trant and metabolite form a trant-metabolite complex, such that the intestinal metabolite is eliminated from the digestive tract along with the sequestrant composition, rather than interacting with or being absorbed by the tissues of the digestive tract. Because the intestinal lites are associated with the development or presence of the behavioral symptom, the g of the sequestrant compositions promotes the elimination of the intestinal metabolite and aids in the treatment of the behavioral symptom and neurological disorder.
In another aspect, the invention provides methods of reducing the amount of one or more intestinal metabolites from a subject having a behavioral symptom of a neurological disorder associated with intestinal hyperpermeability or intestinal dysbiosis.
The methods comprise administering to the subject a sequestrant composition which binds to at least a fraction of at least one intestinal metabolite present in the digestive tract of the subject. As described above, the sequestrant and intestinal metabolite form a sequestrantâmetabolite complex, such that the intestinal metabolite is ated from the digestive tract along with the sequestrant composition, rather than interacting with or being absorbed by the tissues of the digestive tract. Thus, the binding of the sequestrant compositions to intestinal lites which are associated with the development or presence of the behavioral symptom promotes the elimination of the intestinal lites and aids in the treatment of the behavioral symptom and neurological disorder.
In each of the foregoing aspects, in some embodiments the sequestrant composition comprises a multiplicity of les which are biocompatible with, nonâ digestible by, and/or nonâabsorbable by the digestive tract of the subject.
In each of the foregoing aspects, in some embodiments, the sequestrant composition comprises activated carbon particles, a clay, an apatite or hydroxyapatite, a bentonite, a kaolin, a pectin, a cellulose polymer, a cellulose acetate r, a cellulose acetate nate, an ion ge resin, a cholestyramine polymer, a tetraethylenepentamine polymer, a phenolic resin, a boronic acidâpresenting polymer, a catechinâpresenting r, or a zeolite.
In each of the foregoing aspects, in some embodiments, the sequestrant composition comprises an ABâ2004 preparation. The ABâ2004 compositions of the ion comprise spherical activated carbon particles. In some embodiments, the spherical ted carbon particles have a minimum average specific surface area determined by the BrunauerâEmmettâTeller (BET) method of at least 500 mZ/g and a maximum e specific surface area determined by the BrunauerâEmmettâTeller (BET) method less than 4000 mZ/g. In some embodiments, the spherical activated carbon particles have a minimum average particle diameter of at least 0.005 and a maximum average le diameter of less than 1.5 mm. In some embodiments, the spherical activated carbon particles have both (a) a minimum average specific surface area determined by the BrunauerâEmmettâTeller (BET) method of at least 500 mZ/g and a maximum average specific surface area determined by the BrunauerâEmmettâTeller (BET) method less than 4000 mZ/g, and (b) a m average particle diameter of at least 0.005 and a maximum average particle diameter of less than 1.5 mm.
In each of the foregoing aspects, in some embodiments, the sequestrant composition of the ion is ated for controlled release in the lower digestive tract. Such compositions can be administered orally or as a suppository.
In each of the foregoing aspects, in each of the ing embodiments, the neurological disorder can be selected from any of: autism spectrum disorder, an anxiety disorder, Parkinson's Disease, Rett Syndrome, Fragile X Syndrome, Tuberous sis, Multiple Sclerosis, Alzheimerâs Disease, Angelman me, Williams Syndrome, amyotrophic lateral sclerosis, leukodystrophies including Alexander Syndrome, alphaâ synucleinopathies including Lewy Body Dementia, incidental Lewy body disease, Lewy body variant of Alzheimerâs disease, multiple system atrophy, pure autonomic failure, or any combination thereof.
In each of the foregoing aspects, in some embodiments, the behavioral symptom is ed from: tremors, paralysis, dyskinesia, repetitive behaviors, icative symptoms, cognitive disorders, stereotyped behaviors, attachment to physical objects, aphasia, obsessive behaviors, unusual or inappropriate body language, gestures, and/or facial expressions and/or sensorimotor issues, lack of interest in other people, lack of empathy, difficulty grasping nonverbal cues, touch aversion, difficulty in socialization, speech delays, abnormal vocal tone or pitch, vocal repetition, perseveration, conversational difficulty, difficulty communicating needs or desires, inability to understand simple statements or questions, difficulties in processing language subtext, obsessive attachment to unusual objects, preoccupation, intolerance of s in e or environment, ness, abnormal posture, odd ways of moving, fascination with particular objects, hyperâ or hypoâreactivity to sensory input, and clinical irritability.
In each of the ing aspects, in some embodiments, the ogical disorder is autism spectrum disorder and the behavioral symptom is selected from: repetitive ors, communicative symptoms, stereotyped ors, and clinical irritability.
In each of the foregoing aspects, in some embodiments, the subject does not have clinical anxiety or an y disorder.
In each of the foregoing aspects, in some embodiments, the subject does not have chronic kidney disease.
In each of the foregoing aspects, in some ments, the intestinal metabolite is selected from: 4âethylphenol (4âEP), lphenylsulfate (4âEPS), pâcresol (PC), pâcresyl sulfate (PCS), 3âindoxyl sulfate, 3âhydroxy indole, coumaric acid, ydroxyphenyl)â3â ypropionic acid (HPHPA), ydroxyphenyl)propanoic acid, 3â(4âhydroxyâ phenyl)propanoic acid, 3âhydroxy hippuric acid (3HHA), 3âcarboxyâ4âmethylâ5âpropylâ2â furanoic acid (CMPF), 3âhydroxyphenyl acetic acid (3HPA), 4âhydroxyphenyl acetic acid, and 2âhydroxyâ2â(4âhydroxyphenyl)acetic acid.
In each of the foregoing aspects, in some embodiments, the intestinal metabolite is selected from the group consisting of: 4âethylphenol (4âEP), 4âethylphenylsulfate (4â EPS), pâcresol (PC), pâcresyl sulfate (PCS), 3âhydroxy indole, and 3âindoxyl e.
In each of the foregoing s, in some embodiments, the method of treatment comprises monitoring intestinal metabolite levels of the t during the course of treatment.
In each of the foregoing aspects, in some ments, the method of treatment comprises monitoring changes in the behavior of the subject.
In each of the foregoing aspects, in some embodiments, the method of treatment ses administering the trant composition following the appearance of behavioral symptoms of the neurological disorder.
In each of the foregoing aspects, in some embodiments, the method of treatment comprises administering the sequestrant composition prior the appearance of behavioral symptoms of the neurological disorder.
In each of the foregoing aspects, in some embodiments, the method of treatment is repeated as necessary to maintain d levels of intestinal metabolites relative to the levels identified prior to the first administration of the ition. In some embodiments, for a given administration, the composition is different from a composition previously administered.
In each of the foregoing aspects, in some embodiments, the method of treatment comprises ring changes in the behavior of the subject.
Thus, described herein are methods for the treatment, inhibition, or amelioration of one or more or a plurality of neurological ers, leaky gut comorbid with a neurological disorder, or leaky gut independent of a neurological disorder, associated with alterations in the inal microbiome. In some embodiments, the methods comprise the step of administering to a subject a composition that sequesters intestinal lites associated with alterations in the intestinal microbiome and, after having sequestered the intestinal metabolites, is eliminated from the digestive tract Without being metabolized.
In some embodiments, the methods further comprise the step of identifying and/or selecting a subject having elevated levels of one or more intestinal lites associated with alterations in the intestinal microbiome, having symptoms of a disorder associated with alterations in the intestinal microbiome, diagnosed with a disorder associated with alterations in the intestinal microbiome, or at increased risk of developing a disorder associated with alterations in the intestinal microbiome. The compositions to be administered according to the s of the present sure may comprise an adsorbent, polymer, clay, or resin, which may comprise, consist ially of, or consist of one or more of an activated carbon, an apatite or hydroxyapatite, a bentonite, a kaolin, a pectin, a cellulose polymer, a ose acetate polymer, a cellulose acetate nate, an ion exchange resin, a cholestyramine polymer, a tetraethylenepentamine polymer, a ic resin, a boronic acidâpresenting polymer, a catechinâpresenting polymer, a zeolite, and/or a nanoparticle, or any combination thereof. The compositions to be stered according to the methods of the present disclosure may comprise, consist essentially of, or consist of preparations of high surfaceâarea activatedâcarbon particles referred to as ABâ2004 herein. The itions to be administered according to the methods of the present disclosure may further be formulated for controlled release in the lower gastrointestinal tract.
The methods of the present disclosure can be applied to s one or more or a plurality of neurological disorders, e.g., one or more of autism spectrum disorder, schizophrenia, an anxiety disorder, depression, Parkinson's Disease, Rett Syndrome, Fragile X Syndrome, Tuberous Sclerosis, Multiple sis, Alzheimerâs Disease, Angelman me, Williams Syndrome, amyotrophic lateral sclerosis, leukodystrophies including Alexander Syndrome, alphaâsynucleinopathies including Lewy Body Dementia, incidental Lewy body e, Lewy body variant of merâs disease, multiple system atrophy, pure autonomic failure, or any combination thereof.
The methods of the present sure may further be applied to address a neurological disorder, wherein the neurological er presents a leaky gut (intestinal hyperpermeability) in said subject, as well as leaky gut symptoms associated with such neurological disorders, and/or leaky gut symptoms not associated with a neurological The methods according to the present disclosure promote the sequestration of intestinal metabolites associated with intestinal ermeability (leaky gut) or inal dysbiosis (i.e., deleterious changes in the intestinal microbiome), including both microbial metabolites and products of host metabolism of microbial metabolites. Such intestinal metabolites include, without limitation, those generated from the metabolism of tryptophan (e.g., serotonin, 5âhydroxyindoleacetate, kynurenine, kynurenate, anthranilate, xanthurenate, quinolinate, nicotinate, nicotinamide, indole, 3âhydroxy indole, 3âindoxyl sulfate, indole pyruvate, indole propionate, indole acetate, tryptamine), those generated from the metabolism of tyrosine (e.g., 4âethylphenol (4âEP), 4âethylphenylsulfate (4â EPS), pâcresol (PC), yl sulfate (PCS), 4âhydroxyphenylacetate, 2âhydroxyâ2(4â hydroxyphenyl)acetate, trulline), and those generated from the metabolism of benzoate (e.g., benzoate, hippurate, catechol, catechol e), as well as Nâacetylserine, betaâalanine, glutamine, transurocanate, imidazole propionate, phenylacetylglycine, phenol, phenyl sulfate, coumaric acid, 3â(3âhydroxyphenyl)â3âhydroxypropionic acid (HPHPA), 3â(3âhydroxyphenyl)propanoic acid, 3â(4âhydroxyphenyl)propanoic acid, 3â hydroxy hippuric acid , 3âcarboxyâ4âmethylâ5âpropylâ2âfuranoic acid (CMPF), 3â hydroxyphenyl acetic acid (3HPA), 3âmethylâ2âoxovalerate, 4âmethylâ2âoxopentaoate, cysteine, arginine, omithine, 5âmethylthioadenosine, glycylvaline, Fibrinogen Cleavage Peptide, 3âphosphoglycerate, phosphoenolpyruvate, ribose, xylose, docosapentaenoate (n3 DPA; 22:5n3), pentaenoate (n6 DPA; 22:5n6), docosahexaenoate (DHA; 22:6n3), stearate, eicosenoate, dihomoâlinoleate 6), adrenate, l3âHODE+9âHODE, octadecanedioate, lZâHETE, myoâinositol, lâpalmitoylglycerophosphoethanolamine, Nâ alphaâacetylâlâarginine, methyl guanidine, acetylglutamine, â3âacetic acid, indole lactate, lâoleoylglycerophosphoethanolamine, lâpentadecanoylglyceroâ phosphocholine, lâpalmitoleoylglycerophosphocholine, lâstearoylglycerophosphoinositol, lâpalmitoylplasmenylethanolamine, bilirubin (E,E), pantothenate, glycolate (hydroxyacetate), ergothioneine, equol, and/or equol e, or any combination thereof. t being bound by any theory, in some embodiments, a microbial metabolite results from a lic pathway involving tyrosine. In some ments, said microbial metabolite is pâcresol. In some embodiments, said ial metabolite is 4â ethyl phenol. In some embodiments, said metabolite is ol sulfate. In some embodiments, said ial metabolite is 4âethyl phenyl sulfate.
Without being bound by any theory, in some embodiments, a microbial metabolite is an aromatic or heteroaromatic alcohol or sulfate thereof, resulting from the sulfation or sulfonation of said aromatic or heteroaromatic alcohol. In some embodiments, the aromatic alcohol is pâcresol. In some embodiments, the aromatic alcohol is 4âethyl phenol. In some embodiments, the aromatic sulfate is 4âethyl phenyl sulfate.
In some embodiments, said aromatic or heteroaromatic alcohol or sulfate thereof is clic. In some embodiments, said aromatic or heteroaromatic alcohol is bicyclic, lic, or polycyclic. In some embodiments, the heteroaromatic bicyclic alcohol is 3â y indole. In some embodiments the aromatic bicyclic sulfate is 3âindoxyl sulfate.
The terms "aromatic", "heteroaromatic", "alcohol", "sulfate", "sulfation", "sulfonation", "monocyclic", "bicyclic", and "polycyclic" are artârecognized terms of organic chemistry, medicinal chemistry, or pharmaceutical chemistry, and would be y recognized as such by a person of ordinary skill in the art of organic chemistry, medicinal try, or pharmaceutical chemistry.
As used herein, "aromatic" groups (or "aryl" or "arylene" groups) include ic carbocyclic ring systems (e.g., phenyl) and fused polycyclic aromatic ring systems (e.g., naphthyl, biphenyl, and l,2,3,4âtetrahdronaphthyl).
The terms "heteroaryl", "heteroaromatic" or "heteroarylene" as used herein, include aromatic ring systems, including, but not limited to, monocyclic, bicyclic and tricyclic rings, and have 5 to 12 atoms ing at least one heteroatom, such as nitrogen, oxygen, or sulfur. For purposes of exemplification, which should not be construed as limiting the scope of this invention: azaindolyl, benzo(b)thienyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, hiadiazolyl, benzoxadiazolyl, furanyl, imidazolyl, imidazopyridinyl, indolyl, indazolyl, olyl, isothiazolyl, oxadiazolyl, oxazolyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrrolo[2,3âd]pyrimidinyl, pyrazolo[3,4âd]pyrimidinyl, quinolinyl, quinazolinyl, triazolyl, thiazolyl, thiophenyl, tetrazolyl, thiadiazolyl, thienyl, 6Hâpyrrolo[2,3â e] [ l ,2,4]triazolo[4,3âa]pyrazinyl, 6Hâimidazo[ l ,5âa]pyrrolo[2,3âe]pyrazinyl, l,6â dihydropyrazolo[3,4âd]pyrrolo[2,3âb]pyridine, 3Hâ3,4,6,8aâtetraazaâasindacenyl, 3Hâ imidazo[ l yrrolo [2,3 âe]pyrazinyl, pyrazolo [3 ,4âd]pyrrolo [2,3 âb]pyridinyl, l,6â oâl,2,5,6âtetrazaâasâindacenyl, 3Hâ3,4,8aâtriazaâasâindacenyl, xaâ2,5,6â âasâindacenyl, 3 ,6âdihydroâ2,3 ,6âtetraazaâasâindacenyl, l,6âdihydroâdipyrrolo [2,3 âb; 2'3'âd]pyridinyl, 6Hâ3âthiaâ2,5,6âtriazaâasâindacenyl, 4,5âdihydroâlHâbenzo[b]azepinâ 2(3H)âone, 3,4âdihydroquinolinâ2(lH)âone, 2Hâbenzo[b][l,4]oxazinâ3(4H)âone, or 6,7â dihydroâ4Hâpyrazolo[5 , lâc] [ l ,4]oxazinyl or l,6âdihydroimidazo[4,5âd]pyrrolo[2,3â b]pyridine.
The methods ing to the present disclosure may comprise dosing schedules wherein at least one of the sequestrant compositions disclosed herein is administered multiple times per day, daily, or less frequently than daily. According to the methods described herein, dosing of the disclosed compositions may occur every second day, every third day, every fourth day, every fifth day, every sixth day, or every h day.
According to the methods described herein, dosing may initiate prior to, rent with, or following the appearance of one or more or a plurality of symptoms of a neurological disorder, such as autism and/or associated pathologies including inal hyperpermeability (leaky gut) in a subject. The methods as described herein may also incorporate monitoring or a ining of one or more microbial metabolite levels, changes in behavior, and /or changes in gastrointestinal symptoms in a subject before, during, or after the course of therapy.
The methods described herein can be repeated as necessary to treat or prevent one or more of a ity of symptoms of a neurological er, as well as leaky gut symptoms associated with such neurological disorders, and/or leaky gut symptoms not associated with a neurological disorder, and/or to maintain d levels of intestinal metabolites relative to the levels identified prior to the first administration of the composition. For each administration ing to the methods described herein, the composition can be the same as a ition previously administered or can be different from a composition previously administered.
In some embodiments, a neurological disorder as plated herein comprises one or more symptoms selected from the group consisting of: tremors, paralysis, dyskinesia, repetitive behaviors, communicative symptoms, cognitive disorders, stereotyped behaviors, attachment to physical objects, aphasia, obsessive behaviors, unusual or inappropriate body language, gestures, and/or facial sions and/or sensorimotor issues, lack of interest in other people, lack of empathy, difficulty grasping nonverbal cues, touch aversion, difficulty in socialization, speech delays, abnormal vocal tone or pitch, vocal repetition, perseveration, conversational ulty, difficulty communicating needs or desires, inability to understand simple statements or questions, difficulties in processing language subtext, ive attachment to unusual objects, preoccupation, intolerance of changes in routine or environment, clumsiness, al posture, odd ways of moving, fascination with particular objects, and hyperâ or hypoâ reactivity to sensory input, clinical bility or any combination thereof. In some embodiments, the ogical disorder comprises one or more of autism spectrum disorder, schizophrenia, an anxiety disorder, depression, Parkinson's Disease, Rett Syndrome, Fragile X Syndrome, Tuberous Sclerosis, Multiple Sclerosis, merâs Disease, Angelman Syndrome, Williams Syndrome, amyotrophic lateral sclerosis, leukodystrophies including Alexander Syndrome, alphaâsynucleinopathies including Lewy Body ia, incidental Lewy body e, Lewy body variant of Alzheimerâs disease, multiple system atrophy, pure autonomic e, or any combination thereof. In some embodiments, the neurological disorder may comprise autism spectrum disorder that comprises a symptom other than clinical anxiety. In some embodiments, the neurological disorder does not se an anxiety disorder. In some embodiments, the neurological disorder may comprise autism spectrum er that comprises clinical irritability symptoms.
In some embodiments, the s ed may further comprise monitoring, after said administering, changes in a symptom selected from the group consisting of: s, paralysis, esia, tive behaviors, communicative symptoms, cognitive disorders, stereotyped behaviors, attachment to physical objects, aphasia, obsessive behaviors, unusual or inappropriate body language, gestures, and/or facial expressions and/or sensorimotor issues, lack of interest in other people, lack of y, difficulty grasping bal cues, touch aversion, difficulty in socialization, speech delays, abnormal vocal tone or pitch, vocal repetition, perseveration, conversational difficulty, difficulty communicating needs or desires, inability to understand simple statements or questions, difficulties in processing language subtext, obsessive attachment to unusual s, preoccupation, intolerance of changes in routine or environment, clumsiness, abnormal posture, odd ways of moving, fascination with particular s, and hyperâ or hypoâreactivity to sensory input, clinical irritability or any combination thereof.
In some embodiments, the neurological disorder comprises autism spectrum disorder, and the methods as described herein further comprise monitoring the amelioration of a symptom of autism spectrum disorder other than clinical anxiety following the stration of a composition as described herein. In some embodiments, the symptoms of autism spectrum disorder comprise one or more of the following: repetitive behaviors, communicative symptoms, cognitive disorders, ulty in socialization, and irritability. In some embodiments, the sequestrant composition to be administered comprises an 4 preparation.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows urinary 4âEPS Levels in 4EP+ and 4EPâ onized mice.
Germâfree wildâtype C57BL/6 mice were diâcolonized at 4 weeks of age by single oral gavage with either the B. ovams and L. plantarum pair of strains that produces 4âEP or the pair that does not produce 4âEP. High 4âEPS production in vivo with colonization by the 4âEP producing pair (4EP+) and low 4âEPS production with zation by the 4âEP nonâproducing pair (4EPâ) were demonstrated via measurement of 4EPS levels in urine at age 5 weeks, prior to providing an ABâ2004 preparation comprising ASTâ120.
Figure 2 shows that microbiota colonization levels are similar across groups. L. plantarum (left) and B. ovams (right) ed similar levels of colonization in mice regardless of whether they produced 4âEP and regardless of whether the mice were provided an ABâ2004 preparation.
Figure 3 shows that administration of an ABâ2004 preparation normalizes repetitive and anxietyâlike behaviors. (A) Marble burying test of tive behavior. (B) Elevated plus maze test of exploratory behavior (* indicates p < 0.05, ** indicates p < 0.01. Mean +/â Standard Deviation).
Figure 4 shows the results of an Open Field Test. (A) Frequency with which mice d wall area of the open field, as a percentage of total combined entries into the wall area and the center area. (B) Total duration in the wall area ds). (C) Total distance moved during the test (cm).
Figure 5 shows the results of a three chamber test of direct social interaction.
Time spent in chamber with another mouse by: (A) male mice on l diet with microbiota that do not produce 4EP (left bar) and that do produce 4âEP (right bar); and (B) male mice with 4âEP producing microbiota on control diet (left bar) and diet containing an ABâ2004 preparation (right bar). (**p<0.01; Mean +/â Standard Error of the Mean shown.) Figure 6 shows a time course for adsorption of 4âEP by the sequestrants zeolite, bentonite, cellulose (75K), cellulose (15K), and an ABâ2004 preparation. At a 1âhour timepoint, the ABâ2004 ation and the cellulose polymers both y >90% sequestration of 4âEP.
DETAILED PTION Unusually high intestinal or ic levels of certain microbial metabolites, as compared to healthy individuals, can be found in various central nervous system (CNS) diseases and disorders, such as autism spectrum disorder, schizophrenia, an anxiety er, depression, Parkinson's e, Rett Syndrome, Fragile X Syndrome, Tuberous Sclerosis, Multiple sis, Alzheimerâs Disease, Angelman Syndrome, Williams Syndrome, amyotrophic lateral sclerosis, leukodystrophies including Alexander Syndrome, alphaâsynucleinopathies including Lewy Body Dementia, incidental Lewy body disease, Lewy body variant of Alzheimerâs disease, le system atrophy, and/or pure autonomic failure. Reduction of the levels of these microbial metabolites (and hostâ generated modifications of these metabolites) will lead to alleviation and/or reversal of behavioral and/or other neurological symptoms or conditions, as well as, neurological es. Without being bound to any theory, contemplated within the present disclosure are methods and compositions configured to or designed to lower the systemic levels of microbial metabolites (and hostâgenerated modifications of these metabolites) to levels commensurate with (e.g., the same as or lower than) healthy individuals by administering or providing to a subject (e.g., a human, mammal or domestic animal) having such a central nervous system (CNS) e or disorder associated with raised systemic levels of such microbial metabolites (and hostâgenerated modifications of these lites), a nonâabsorbable composition, such as a r, clay, resin, carbonâbased or other chemical moiety, which is capable of or configured to selectively bind microbial lites (and hostâgenerated modifications of these metabolites) in the gut thereby alleviating, inhibiting, or mitigating absorption and/or ort of the ial metabolites (and hostâgenerated modifications of these metabolites) into peripheral tissues. The liteâladen composition will then be excreted from the subject in the feces, thereby permanently removing the microbial metabolites (and hostâgenerated modifications of these metabolites) and improving said CNS symptoms, diseases and/or disorders in said subject. Certain microbial metabolites (e.g., 4âethylphenol (4âEP) and pâ cresol (PC)) have been identified as being correlated with and are believed to be causal of neurodevelopmental and behavioral disorders such as ASD. These metabolites may gain adventitious entry into systemic circulation through the "leaky gut" comorbidity often associated with such disorders. Once in systemic ation these metabolites may act directly on relevant metabolic and ing pathways to contribute to disease progression, systems and/or ogy. In addition, metabolites can be further metabolized by normal host processes to create new metabolites (e.g., 4âEPS and PCS) that can have adverse ogical effects, as well.
Thus, as disclosed in the experimental examples below, 4âEP overâproducing mice were experimentally created by diâcolonization for 3â5 weeks of germâfree mice with engineered Bacteroides ovatus and Lactobacillus plantarum. In standard mouse behavioral tests, these 4EP overâproducing mice were shown to demonstrate ASDâ associated behaviors and symptoms; and, further, it was shown that the stration of sequestering agents (e.g,, ABâ2004) that are capable of binding 4âEP and other metabolites in these mice can ameliorate such sociated behaviors and symptoms.
These s were surprising: a previous study had shown that 4âEPS (the hostâsulfated version of 4âEP), when provided as a single bolus injection intraperitoneally, engendered symptoms of anxiety in naive, wildâtype mice but did not engender any core symptoms of autism spectrum disorder.
By sequestering these metabolites at the source of their production, e.g., in the gut of the subject, the translocation of the microbial metabolites (and hostâgenerated modifications of these metabolites) into peripheral tissues will be minimized or eliminated. The net effect is the minimization of the impact of these metabolites and their r metabolites on the subject. Using a nonâabsorbable al, such as a patible polymer or an activated carbon preparation such as an ABâ2004 preparation, the target metabolites are permanently removed through normal passage through and excretion from the gut.
Some atives of the methods described herein comprise methods of treating, ting, or ameliorating a neurological disorder associated with an alteration in the intestinal microbiome of a subject, such as a human, mammal, or domestic animal, wherein said methods comprise administering or providing to said subject a composition, which sequesters said microbial metabolites (and hostâgenerated modifications of these metabolites), n said composition having tered intestinal metabolites is ated from the digestive tract without being metabolized. In some embodiments, the method further comprises the step of identifying and/or selecting a subject having elevated levels of one or more microbial metabolites (and hostâgenerated modifications of these metabolites). According to some embodiments, the methods described herein may comprise methods of treating, inhibiting, or ameliorating leaky gut or leaky gut symptoms associated with said one or more neurological disorders. According to some embodiments, the methods described herein may comprise methods of treating, inhibiting, or rating leaky gut or leaky gut symptoms not associated with said one or more neurological disorders. According to some embodiments, the methods described herein may comprise methods of treating, inhibiting, or rating one or more neurological disorders independent of any effect on leaky gut or leaky gut symptoms.
For es of the present disclosure, the following definitions are provided.
As used , when referring to the term "intestinal dysbiosis" means an imbalance or maladaptation of the ïŹora or microbiota within the gut or ines, and particularly the small intestine. Such dysbiosis is characterized by a change in the composition of the intestinal or gut microbiome, in terms of the species/strains which are present and/or the relative abundance or proportion of the s/strains which are present, in which the change has a deleterious effect on the host organism. The rious effect on the host organism can result from microbiomeâmediated s in electrolyte balance, biofilm formation, integrity of the barrier formed by the intestinal epithelial , or the e from the microbiome of metabolites which are directly (e.g., as toxicity or ors) or indirectly (e.g., as preâcursors to toxins or effector) injurious to the health of the host.
As used herein, the term "intestinal hyperpermeability" means abnormal increased permeability of the barrier formed by the intestinal epithelial lining between the intestinal lumen and the surrounding issues. Such hyperpermeability may result from inïŹammation of the intestinal lining and/or failure of the tight ons between cells of the intestinal epithelium, which allows the passage of substances from the lumen into the surrounding tissues where some may enter the peritoneal caVity and/or systemic circulation. Because of this leakage of substances from the gut or intestinal lumen, intestinal hyperpermeability may be referred to as "leaky gut" or "leaky gut me." As used herein with respect to sequestrant compositions, the term "biocompatible" means that the sequestrant composition does not have clinically significant toxic or injurious effects, locally or ically. The term "biocompatible" does not exclude the possibility that a sequestrant composition may affect the passage of partially digested food (e.g., chyme, chyle, feces) through the intestines or induce some degree of diarrhea or constipation.
As used herein with respect to sequestrant compositions, the term "indigestible" means that the sequestrant composition is ntially resistant to degradation in the environment of the gastrointestinal tract such that at least 50%, and preferably more than 60%, 70%, 80% 90% or 95% of the sequestrant composition by weight is present in bulk (e.g., particulate, granular, fibrous) and not dissolved form when eliminated from the As used herein with respect to sequestrant compositions, the term "nonâ absorbable" means that the sequestrant composition is substantially ble of being absorbed by the lining of the gastrointestinal epithelium such that less than 25%, and preferably less than 20%, 15%, 10%, 5% or 1% of the sequestrant composition by weight is absorbed by the gastrointestinal epithelium.
As used herein with respect to metabolites and symptoms or disorders, the term "associated" means that the presence or level of a metabolite has been statistically icantly ated (at least p < 0.05, preferably p < 0.01 or p < 0.001) with the presence or degree of the symptom or disorder, and/or that the metabolite or a reaction product of the metabolite has been causally or mechanistically related to the development, maintenance or degree of the symptom or disorder.
As used herein, the term m spectrum disorder" or "ASD" means a neurological and developmental disorder that begins early in ood and has a range of symptoms including: impaired social interactions; a disturbance in the comprehension of language; impaired and delayed verbal and written communication; restricted repetitive and stereotyped patterns of behavior, interests and activities; hyperactivity; short attention span; impulsivity; siveness; selfâinjurious behaviors; and, particularly in young children, temper tantrums. ASD is now understood to e disorders previously identified as distinct: Autistic er, Aspergerâs Disorder and Pervasive Developmental Disorder (Not Otherwise Specified). See, for example, The Diagnostic and Statistical Manual ofMental Disorders, Fourth n, Washington, DC, an Psychiatric Association, 1994 ("DSMâIV"). Disorders related to ASD include Rett Syndrome and Childhood Disintegrative er.
As used herein, the term "anxiety disorder" means a disorder terized by an abnormal state of worry or fear, and includes subtypes such as acute stress disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, agoraphobia, obsessiveâcompulsive disorder, raumatic stress disorder, selective mutism, or separation anxiety. Symptoms of anxiety vary depending on the type of anxiety experienced. The term "clinical anxiety" means an abnormally intense and disruptive level of anxiety, which is distinctly above normal levels of anxiety ated with a stressful situation. Clinical y can be associated with any of the disorders listed above, or can be secondary to or symptomatic of another neurological disorder such as autism spectrum disorder (ASD) or schizophrenia. See, generally, DSMâIV, pages 393â As used , the term "irritability" means an abnormally intense and disruptive level of irritability, including a tendency to be em» annoyed, upset, or pmxmtc to anger; which is distinctly above normal levels of irritability associated with an unpleasant or stressful situation. Clinical irritability can be associated With disorders including, Without limitation, generalized anxiety disorder, autism spectrum disorders (ASD), postâtraumatic stress disorder, attentionâdeficit er (ADD), attentionâdeficit hyperactivity disorder , manic disorders, Alzheimerâs Disease, borderline personality disorder, antisocial ality disorder, and schizoaffective er, or can be secondary to or symptomatic of another neurological disorder. Irritability can be measured clinically in humans using the Aberrant Behavior Checklist as described in Marcus er al. (2009), J.
Am. Acad. Child Adolesc. Psychiatry, 48(ll):lllOâlll9, and in Aman and Singh, Aberrant Behavior Checklist: Manual. East Aurora, NY: Slosson Educational Publications; 1986.
"Subject" as used herein, refers to a human or a man mammal including but not limited to a dog, cat, horse, donkey, mule, cow, domestic buffalo, camel, llama, alpaca, bison, yak, goat, sheep, pig, elk, deer, domestic antelope, or a nonâhuman primate selected or identified for removal of one or more ial metabolites (and hostâ generated modifications of these metabolites) or selected or identified for treatment, inhibition, amelioration of a ogical disease or neurological disorder, or any symptom thereof, associated with an alteration in the intestinal microbiome, including Without limitation autism spectrum disorder (ASD), schizophrenia, an anxiety disorder, depression, Parkinson's e, Fragile X, Rett Syndrome, Tuberous Sclerosis, leukodystrophies including Alexander me, alphaâsynucleinopathies including Lewy Body ia, and/or Alzheimerâs Disease.
"Subject suspected of having" refers to a subject ting one or more al indicators of a e or condition. In certain embodiments, the disease or condition may comprise one or more of autism spectrum disorder, an anxiety disorder, Fragile X, Rett syndrome, tuberous sis, obsessive compulsive disorder, attention deficit er, and/or schizophrenia.
"Subject in need thereof â refers to a t selected or identified as one being in need of a composition that removes or sequesters one or more microbial metabolites (and hostâgenerated modifications of these metabolites) or one in need of a treatment, inhibition, amelioration of a neurological disease or ogical disorder associated with an alteration in the inal iome such as autism spectrum disorder, an anxiety disorder, Parkinson's Disease, Rett Syndrome, Fragile X Syndrome, Tuberous Sclerosis, Multiple Sclerosis, Alzheimerâs e, Angelman me, Williams Syndrome, amyotrophic lateral sclerosis, leukodystrophies including Alexander Syndrome, alphaâ synucleinopathies including Lewy Body Dementia, incidental Lewy body disease, Lewy body variant of Alzheimerâs disease, multiple system atrophy, pure autonomic failure, or any combination f.
A peutic effect" relieves or alleviates, to at least some extent, one or more of the symptoms of a disease or disorder, and es curing the disease or disorder.
"Curing" means that the symptoms of active disease are eliminated. However, certain longâterm or permanent effects of the disease may exist even after a cure is obtained (such as tissue damage).
"Amelioration" refers to a lessening of severity of at least one indicator of a condition or disease. In certain embodiments, amelioration includes a delay or slowing in the progression of one or more indicators of a condition or disease. The ty of indicators can be determined by subjective or objective es which are known to those skilled in the art.
"Modulation" refers to a perturbation of function or activity. In certain embodiments, modulation refers to an se in gene expression. In certain embodiments, modulation refers to a decrease in gene expression. In certain embodiments, modulation refers to an increase or decrease in total serum levels of a specific protein. In certain embodiments, modulation refers to an increase or decrease in free serum levels of a ic protein. In certain embodiments, modulation refers to an se or decrease in total serum levels of a ic nonâprotein factor, e.g., a metabolite. In certain embodiments, modulation refers to an increase or decrease in free serum levels of a specific nonâprotein factor. In certain embodiments, modulation refers to an se or decrease in total bioavailability of a specific protein. In certain embodiments, modulation refers to an increase or decrease in total ilability of a specific nonâprotein factor.
"Lipid number" is an artârecognized term used to define the structural es of fatty acids and lipids. For example, in "docosapentaenoate (n3 DPA; 22:5n3)", "22" refers to the total number of carbons; "5" refers to the total number of rated (double) bonds and "n3" refers to the position of the carbon atom where the first unsaturation occurs, as numbered from the end opposite of the carboxylate group.
SEQUESTRANT PREPARATIONS In some embodiments, the compositions to be administered according to the methods described herein may comprise, consist essentially of, or consist of one or more of an adsorbent, polymer, clay or resin, wherein said adsorbent, polymer, clay or resin may r comprise an ted carbon, an apatite or hydroxyapatite, a kaolin, a bentonite, a pectin, a cellulose polymer, an ion exchange resin, a cholestyramine polymer, a tetraethylenepentamine polymer, a phenolic resin, a boronic acidâpresenting polymer, a catechinâpresenting polymer, a zeolite, and/or a nanoparticle, or any ation f.
In some embodiments, according to the methods of the present disclosure, the sequestrant composition to be administered comprises, consists essentially of, or ts of a carbon material or activated carbon material. Said carbon materials or activated carbon materials have average particle sizes of 5â40 nm, 25â100 nm, 50â300 nm, 150â500 nm, 300 nmâl um, 0.5 umâ2 um, I umâ5 um, 2.5â10 um, 6â20 um, l5â50 um, 30â100 um, 75â150 um, 100â300 um, 250â500 um, 300â750 um, 600 umâl mm, or greater than 1 mm or a size that is within a range d by any two of the aforementioned sizes. In some ments, said carbon materials or activated carbon materials have particle sizes of 300 umâl mm, lâ3 mm, 2â5 mm, or greater than 5 mm or a size that is within a range defined by any two of the aforementioned sizes. Said carbon materials or activated carbon materials also comprise a plurality of pores and a specific surface area in the range of from 20 mZ/g to 5000 mZ/g, such as, e.g., 20, 50, 100, 250, 500, 750, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500 or 5000 mZ/g or a specific surface area within a range defined by any two of the aforementioned surface areas. Specific surface area can be determined using known methods, such as, for example, the method of Bruanauer, Emmett and Teller (J. Am. Chem. Soc. (1938), â311) and/or mercury porosimetry.
See, e.g., ASTM Test Methods D3663, D6556, and D4567, each of which is orated by nce in its entirety.
Said carbon materials or activated carbon materials may additionally have a specific pore volume (determined on the basis of pores having a diameter of 1.7 nm to 100 nm) that is from 0.1 cm3/g to 1.5 cm3/g, from 0.1 cm3/g to 0.8 cm3/g, from 0.1 cm3/g to 0.7 cm3/g, from 0.1 cm3/g to 0.6 cm3/g, from 0.1 cm3/g to 0.5 cm3/g, from 0.2 cm3/g to 0.8 cm3/g, from 0.2 cm3/g to 0.7 cm3/g, from 0.2 cm3/g to 0.6 cm3/g, from 0.2 cm3/g to 0.5 cm3/g, from 0.3 cm3/g to 1 cm3/g, from 0.3 cm3/g to 0.9 cm3/g, from 0.3 cm3/g to 0.8 cm3/g, from 0.3 cm3/g to 0.7 cm3/g, from 0.3 cm3/g to 0.6 cm3/g, or from 0.3 cm3/g to 0.5 cm3/g or within a range defined by any two of the aforementioned values, as measured by a method for determining pore diameters and specific pore volumes, such as that described in Barrett, Joyner and Halenda (1951), J. Am. Chem. Soc. 73:373-380 and ASTM 03 (2008) (the method referred to herein as the "BJH method"), both of which are expressly incorporated herein by reference in their entireties, and by the method of mercury porosimetry (e.g., using a y meter, such as, for e, the Micromeritics Autopore V 9605 Mercury Porosimeter (Micromeritics Instrument Corp., Norcross, GA) in accordance with the manufacturer's instructions). See e.g., ASTM 3663, ASTM Dâ4284â12 and D6761â07 (2012), all of which are incorporated herein by reference. Said carbon material or activated carbon material may further have a mean pore diameter in the range of from 2 nm to 100 nm, as measured by the BJH method and/or mercury porosimetry. More typically, the carbon material or activated carbon material may have a mean pore diameter in the range of from 2â5 nm, from 3â9 nm, from 6â15 nm, from 10 nm to 90 nm or a size that is within a range defined by any two of the aforementioned sizes, as measured by the BJH method and/or mercury porosimetry. In some ments, the mean pore diameter is in the range of from 10 nm to 80 nm, or from 10 nm to 70 nm, or from 10 nm to 60 nm, and often from 10 nm to 50 nm or a size that is within a range defined by any two of the aforementioned sizes, as determined by the BJH method and/or mercury porosimetry. In some embodiments, the mean pore diameter is in the range of from 20 nm to 100 nm or a size that is within a range defined by any two of the aforementioned sizes, as measured by the B]H method and/or mercury porosimetry. In certain of these embodiments, the mean pore diameter is in the range from 20 nm to 90 nm, or from 20 nm to 80 nm, or from 20 nm to 70 nm, or from 20 nm to 60 nm, or from 10 nm to 50 nm or a size that is within a range d by any two of the aforementioned sizes, as determined by the B]H method and/or mercury porosimetry.
In some embodiments, the methods of the present disclosure plate the administration of an adsorbent comprising an ABâ2004 preparation. As used herein, the term "ABâ2004" or "ABâ2004 preparation" refers to a preparation of spherical activated carbon particles (a) having a minimum average specific surface area determined by the BrunauerâEmmettâTeller (BET) method of at least 500 mZ/g, at least 600 mZ/g, at least 700 mZ/g, or at least 800 mZ/g and a maximum e ic e area determined by the BrunauerâEmmettâTeller (BET) method less than 2000 mZ/g, less than 3000 mZ/g, or less than 4000 mZ/g, and/or a minimum e specific surface area determined by Langmuir's adsorption equation of at least 500 mZ/g, at least 1000 mZ/g or at least 2000 mZ/g; and (b) having a m average particle diameter of at least 0.005, at least 0.01 mm, at least 0.05 mm, and a maximum e le diameter of less than 1.5 mm, less than 1 mm, or less than 0.2 mm. In some embodiments, the ABâ2004 preparation comprises activated al particles comprising not less than 0.5 wt % nitrogen atoms.
Said spherical activated carbon can be prepared using a thermoplastic resin, thermosetting resin, or ion exchange resin containing nitrogen atoms, as a carbon source; where said thermoplastic resin or ion exchange resin may contain a monomer selected from the group consisting of acrylonitrile, ethylacrylonitrile, methylacrylonitrile, diphenylacrylonitrile, and acrylonitrile; and said thermosetting resin may contain a monomer selected from the group consisting of melamine and urea. Said spherical activated carbon may further be surfaceâunmodified, and may have a total acidic group content from 0.40 to 1.00 meq/g, less than 0.40 meq/g (but not zero), less than 0.30 meq/g (but not zero), and/or a total amount of basic groups from 0.40 to 1.10 meq/g. Alternatively, said spherical activated carbon can be surface modified, for example by ion, which can be performed in an atmosphere containing from 0.1 vol % to 50 vol % oxygen, from 1 vol % to 30 vol %, or from 3 vol % to 20 vol %; at a temperature from 300° C to 800° C or from 320° C to 600° C. Said spherical activated carbon can be further modified, or may alternatively be surface modified by other procedures, for example by reduction, which can be performed at a temperature from 800° C to 1200° C or from 800° C to 1000° C.
Exemplary carbon/activated carbon materials, also known as "activated charcoal," that are useful in the manufacture of sorbable spherical particle preparations, including ABâ2004 preparations, are available from numerous manufacturers, including Kureha Corporation (Japan), Aditya Birla Group (India), Orion Engineered Carbons SA.
(Luxembourg), Asbury Graphite Mills, Inc. y, NJ), Cabot Corporation (Boston, MA), Continental Carbon Company (Houston, TX), Sid Richardson Carbon & Energy Co. (Fort Worth, TX) and s Graphite and Carbon (Switzerland). Various activated carbon/activated carbon products from these and other manufacturers can either be used in ABâ2004 preparations, or can be adapted or modified for use in ABâ2004 preparations.
Methods for producing a spherical activated carbon, including certain spherical activated carbon ABâ2004 preparations of the invention, can be found in U.S. Patent No. 9,877,987, U.S. Patent No. 8,309,130, U.S. Patent No. 7,651,974, U.S. Patent No. 4,761,284 and U.S. Patent No. 4,681,764, each of which is hereby expressly orated by reference in its entirety, and especially with respect to the disclosure of methods of making spherical activated carbon compositions and the spherical activated carbon compositions made thereby.
In some embodiments, according to the methods of the present disclosure, the sequestrant composition may se one or more of an apatite or hydroxyapatite. Said apatite or hydroxyapatite may have average particle sizes of 5â40 nm, 25â100 nm, 50â300 nm, 150â500 nm, 300 nmâ1 um, 0.5 umâ2 um, 1 umâ5 um, 2.5â10 um, 6â20 um, 15â50 um, 30-100 um, 75â150 um, 100â300 um, 250â500 um, 300â750 um, 600 umâl mm, or greater than 1 mm or a size that is within a range defined by any two of the aforementioned sizes. In some embodiments, said apatite or hydroxyapatite may have particle sizes of 300 umâl mm, 1â3 mm, 2â5 mm, or greater than 5 mm or a size that is within a range d by any two of the aforementioned sizes. Said e or hydroxyapatite may also comprise a plurality of pores and a specific surface area in the range of from 20 mZ/g to 500 mZ/g, such as, e.g., 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 mZ/g or a specific surface area within a range d by any two of the aforementioned surface areas. Specific surface area can be determined using known s, such as, for e, the method of Bruanauer, Emmett and Teller and/or mercury porosimetry, as above.
An apatite or yapatite sequestrant may additionally have a ic pore volume (determined on the basis of pores having a diameter of 1.7 nm to 100 nm) that is from 0.1 cm3/g to 1.5 cm3/g, from 0.1 cm3/g to 0.8 cm3/g, from 0.1 cm3/g to 0.7 cm3/g, from 0.1 cm3/g to 0.6 cm3/g, from 0.1 cm3/g to 0.5 cm3/g, from 0.2 cm3/g to 0.8 cm3/g, from 0.2 cm3/g to 0.7 cm3/g, from 0.2 cm3/g to 0.6 cm3/g, from 0.2 cm3/g to 0.5 cm3/g, from 0.3 cm3/g to l cm3/g, from 0.3 cm3/g to 0.9 cm3/g, from 0.3 cm3/g to 0.8 cm3/g, from 0.3 cm3/g to 0.7 cm3/g, from 0.3 cm3/g to 0.6 cm3/g, or from 0.3 cm3/g to 0.5 cm3/g or within a range defined by any two of the aforementioned values, as measured by a method for determining pore diameters and specific pore volumes, such as the BJH method, or by mercury porosimetry, as above. Said apatite or hydroxyapatite sequestrants may further have a mean pore diameter in the range of from 10 nm to 100 nm, as measured by the BJH method and/or mercury porosimetry. More typically, the apatite or hydroxyapatite sequestrant may have a mean pore er in the range of from 2 nm to 90 nm, as measured by the BJH method and/or mercury porosimetry. In some embodiments, the mean pore er is in the range of from 2â5 nm, from 3â9 nm, from 6â15 nm, from 10 nm to 80 nm, or from 10 nm to 70 nm, or from 10 nm to 60 nm, and often from 10 nm to 50 nm or a size that is within a range defined by any two of the entioned sizes, as determined by the BJH method and/or mercury porosimetry. In some embodiments, the mean pore diameter is in the range of from 20 nm to 100 nm, as measured by the BJH method and/or mercury porosimetry. In certain of these embodiments, the mean pore diameter is in the range from 20 nm to 90 nm, or from 20 nm to 80 nm, or from 20 nm to 70 nm, or from 20 nm to 60 nm, or from 10 nm to 50 nm or a size that is within a range d by any two of the aforementioned sizes, as determined by the B]H method and/or mercury metry. Exemplary forms of e or hydroxyapatite sequestrants include milled particles, spray dried particles, spherical nanoparticles, and spherical microparticles.
In some embodiments according to the methods of the present disclosure, the sequestrant compositions may comprise, consist essentially of, or t of one or more of an ingestible porous silica nd (e.g., calcium silica hydrate), such as the Microâ Cel ETM product (Imerys Graphite and Carbon, Bironico Switzerland). In some embodiments, according to the s of the present disclosure, the sequestrant composition comprises an ingestible porous silica compound. Said ingestible porous silica compound may have average particle sizes of 5â40 nm, 25â100 nm, 50â300 nm, 150â500 nm, 300 nmâl um, 0.5 umâ2 um, I umâ5 um, 2.5â10 um, 6â20 um, l5â50 um, â100 um, 75â150 um, 100â300 um, 250-500 um, 300â750 um, 600 umâl mm, or greater than 1 mm or a size that is within a range defined by any two of the entioned sizes. In some embodiments, said ingestible porous silica compound may have particle sizes of 300 umâl mm, 1â3 mm, 2â5 mm, or greater than 5 mm or a size that is within a range defined by any two of the aforementioned sizes. Said ingestible porous silica compound may also comprise a plurality of pores and a specific surface area in the range of from 20 mZ/g to 500 mZ/g, such as, e.g., 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, or 500 mZ/g or a specific surface area within a range defined by any two of the aforementioned surface areas. Specific surface area can be determined using known methods, such as, for example, the method of Bruanauer, Emmett and Teller and/or mercury porosimetry, as above.
Said ingestible porous silica compound may additionally have a specific pore volume (determined on the basis of pores having a diameter of 1.7 nm to 100 nm) that is from 0.1 cm3/g to 1.5 cm3/g, from 0.1 cm3/g to 0.8 cm3/g, from 0.1 cm3/g to 0.7 cm3/g, from 0.1 cm3/g to 0.6 cm3/g, from 0.1 cm3/g to 0.5 cm3/g, from 0.2 cm3/g to 0.8 cm3/g, from 0.2 cm3/g to 0.7 cm3/g, from 0.2 cm3/g to 0.6 cm3/g, from 0.2 cm3/g to 0.5 cm3/g, from 0.3 cm3/g to l cm3/g, from 0.3 cm3/g to 0.9 cm3/g, from 0.3 cm3/g to 0.8 cm3/g, from 0.3 cm3/g to 0.7 cm3/g, from 0.3 cm3/g to 0.6 cm3/g, or from 0.3 cm3/g to 0.5 cm3/g or within a range defined by any two of the entioned values, as measured by a method for determining pore diameters and ic pore s, such as the BJH method, or by y porosimetry, as above. Said ingestible porous silica compound may further have a mean pore diameter in the range of from 2 nm to 100 nm, as measured by the BJH method and/or mercury porosimetry. More typically, the ingestible porous silica compound may have a mean pore er in the range of from 2 nm to 90 nm, as measured by the BJH method and/or mercury porosimetry. In some ments, the mean pore diameter is in the range of from 2â5 nm, from 3â9 nm, from 6â15 nm, from 10 nm to 80 nm, or from 10 nm to 70 nm, or from 10 nm to 60 nm, or from 10 nm to 50 nm or a size that is within a range defined by any two of the aforementioned sizes, as determined by the BJH method and/or mercury porosimetry. In some embodiments, the mean pore diameter is in the range of from 20 nm to 100 nm, as measured by the BJH method and/or mercury porosimetry. In certain of these ments, the mean pore diameter is in the range from 20 nm to 90 nm, or from 20 nm to 80 nm, or from 20 nm to 70 nm, or from 20 nm to 60 nm, or from 10 nm to 50 nm or a size that is within a range defined by any two of the aforementioned sizes, as determined by the B]H method and/or mercury porosimetry. Exemplary ingestible porous silica nds are described in, for example, US. Patent No. 6,666,214.
In some embodiments, according to the methods of the present disclosure, the sequestrant compositions may comprise one or more ingestible hydrocarbon or protein polymers. Exemplary ingestible polymers include but are not limited to guars, gums, chondroitinâbased polymers, polyethyleneâoxide polymers &, polyester, polylactic acid, polylacticâcoâglycolic acid, cellulose, nitrocellulose, chitin, chitosan, polyethylene oxide, poly (BâbenzylâLâaspartate), poly rolactone), polyglycolide, poly(DLâlactideâcoâ glycolide), tylcyanoacrylate, alginate, dipic anhydride), 1,5âdioxepanâ2âone, D,Lâdilactide, polyvinyl acetate phthalate, methacrylic acidâmethacrylic acid ester copolymers, trimellitate, poly(methacrylic acid), polyurethanes, polysiloxanes, polymethyl methacrylate, polyvinyl alcohol, polyethylene, polyvinyl pyrrolidone, epoxy resins, poly2â hydroxyethylmethacrylate, polyâNâvinyl pyrrolidone, polyvinyl alcohol, polyacrylic acid, polyacrylamide; polyethyleneâcoâvinyl e, polylactides, polyglycolides, polylactideâ coâglycolides, polyanhydrides, and polyorthoesters and/or polyfluoroacrylic acid, or others as are known to those of skill in the art, or any combination thereof. These and many other pharmaceutically acceptable polymers are available from DowDuPont, Midland, In some embodiments according to the methods of the present disclosure, the sequestrant itions may comprise one or more of a cellulose polymer. Exemplary cellulose polymers include but are not limited to cellulose ethers, ethylcellulose, methylcellulose, hydroxyethylcellulose, ymethylpropylcellulose, carboxymethylcellulose, carboxymethyl ethylcellulose, hydroxypropylcellulose, cellulose esters, cellulose e, cellulose acetate trimellitate, hydroxypropyl methyl ose phthalate, ypropyl methylcellulose acetate ate, cellulose acetate phthalate, and/or ose acetate propionate, or others as are known to those of skill in the art, and any combination f. Exemplary cellulose polymers may comprise cellulose e propionate having an average molecular weight of 10K, 25K, 50K, 100K, 150K, 200K, 250K, 500K, 750K, 1000K or more, or within a range defined by any two of the values disclosed herein, as determined by gel permeation chromatography.
In some embodiments according to the methods of the present disclosure, the compositions may comprise one or more of a weak base amineâcontaining resin and/or sepiolite. Exemplary amine containing resins include but are not limited to polyacrylamide, chitosan, amineâderivatized poly(methyl acrylate), epoxyamine resins, and/or any amine tive of any polymer or resin otherwise disclosed herein, or any combination thereof.
In some embodiments according to the methods of the present disclosure, the sequestrant compositions may comprise, consist essentially of, or consist of one or more of an ion exchange resin. Exemplary ion ge resins may comprise cellulose, polystyrene, acrylic ester, sulfonic acid r, ic acid ester, polyethylenimine, polyamide, polyâstyreneâdivinylbenzene, or polyâphenolâformaldehyde, or other nds. Commercially available ion exchange resins include but are not limited to oseÂź, exÂź, AmberliteÂź, AmberlystÂź, or .
In some embodiments, the sequestrant composition may comprise a clay compound. In some embodiments, the compositions as described herein may comprise bentonite, alumina, or other clay compounds as are known in the art. In some embodiments, the compositions as disclosed herein may comprise a zeolite. In some further embodiments, said compositions may comprise clinoptilolite. In some embodiments, said clinoptilolite may have a general stoichiometry of (Na,K,Ca)2_ 3A13(Al,Si)2Si13036- lZHZO.
It is understood by those of skill in the art that the resins, clays, polymers, cellulose derivatives, etc., disclosed herein or otherwise known in the art can be modified by conventional means such as by crosslinking or ion to be suitable for stration according to the methods of the present disclosure.
In some embodiments, the sequestrant ition can be administered multiple times. In some further embodiments, the same sequestrant composition is administered each time. In some further embodiments, the sequestrant composition to be administered in subsequent administrations can be different from that administered in the initial administration or in any previous administration. In some embodiments, further administrations can be employed at intervals as described herein, for such duration as is necessary to maintain reduced levels of intestinal metabolites ve to the levels fied prior to the first administration of the sequestrant composition.
In some ments according to the methods of the present disclosure, the sequestrant compositions and methods may further comprise a probiotic ition or administration of a probiotic composition, e.g., before, during, or after administration of the composition comprising, consisting essentially of, or consisting of the one or more sequestration agents. In some embodiments, the sequestrant compositions and or methods may comprise one or more of Prevotella species, Bifido bacteria species, Parabacteriodes species, (e.g., P. merdae, P. distasonis), Faecalibacterium species, (e.g., F. itzii), Eubacterium species, C0pr0c0ccus s, Lactobacillus reuteri, Lactobacillus rhamnosis, oides caccae, iodes ovatus, Bacteroides fragilis, Bacteroides vulgatus, and/or Bacteroides thetaiotaomicron, or any combination thereof, which can be administered before, during, or after administration of the composition comprising the one or more sequestration agents. In some embodiments, the methods of the present disclosure further comprise administration of a tic composition as a component of a sequestering composition. In some embodiments, the methods of the present disclosure further comprise administration of a probiotic composition in addition to a sequestering composition.
FORMULATIONS AND METHODS OF ADMINISTRATION "Administering" refers to providing a pharmaceutical agent, dietary supplement, or composition to a t, and includes, but is not limited to, administering by a medical professional and selfâadministration. Administration of the compounds disclosed herein or the ceutically acceptable salts thereof can be via any of the accepted modes of stration for agents that serve similar utilities including, but not limited to, orally, intraperitoneally, or rectally. Oral administrations are customary in administering the compositions that are the subject of the preferred embodiments. However in some ments, the compositions are administered rectally, such as by enema or itory. In some embodiments, administration of the compounds may occur outside the body, for example, by apheresis or is.
The term "agent" es any substance, molecule, element, compound, entity, or a ation thereof. It includes, but is not limited to, e. g., protein, polypeptide, peptide or mimetic, small c molecule, polysaccharide, polynucleotide, polymer, resin, organic or inorganic microparticle, c or inorganic nanoparticle, and the like. It can be a natural product, a synthetic compound, or a chemical compound, or a combination of two or more nces.
The compounds useful as described above can be formulated into pharmaceutical compositions and/or dietary supplements for use in treating, inhibiting, or ameliorating a ogical disease or neurological disorder associated with an alteration in the intestinal microbiome such as autism Spectrum Disorder (ASD), schizophrenia, an anxiety disorder, depression, Parkinson's Disease, Fragile X, Rett Syndrome, Tuberous Sclerosis, leukodystrophies ing Alexander Syndrome, alphaâsynucleinopathies including Lewy Body Dementia, and/or Alzheimerâs Disease. Standard pharmaceutical and/or dietary supplement formulation techniques are used, such as those disclosed in Remington's The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins (2005), incorporated herein by reference in its entirety. Accordingly, some embodiments include pharmaceutical and/or dietary supplement compositions comprising, consisting essentially of, or ting of: (a) a safe and eutically effective amount of one or more compounds described , or ceutically able salts thereof; and (b) a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.
The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, diluents, emulsifiers, binders, buffers, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like, or any other such compound as is known by those of skill in the art to be useful in ing pharmaceutical formulations. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ients can also be incorporated into the compositions. In addition, various adjuvants such as are commonly used in the art can be included. These and other such compounds are described in the literature, e.g., in the Merck Index, Merck & y, Rahway, NJ. Considerations for the inclusion of various components in pharmaceutical compositions are described, e.g., in Gilman er al. (Eds.) (1990); Goodman and Gilmanâs: The Pharmacological Basis of Therapeutics, 8th Ed., Pergamon Press.
Some examples of substances, which can serve as pharmaceuticallyâacceptable carriers or components thereof, are sugars, such as e, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl ose; powdered tragacanth; malt; n; talc; solid lubricants, such as stearic acid and ium stearate; calcium sulfate; ble oils, such as peanut oil, seed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the TWEENS; wetting agents, such as sodium lauryl sulfate; coloring agents; ïŹavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogenâfree water; ic saline; and/or phosphate buffer solutions, or any combination thereof.
The compositions described herein are preferably provided in unit dosage form.
As used herein, a "unit dosage form" is a composition containing an amount of a compound that is suitable for administration to a subject, in a single dose, according to good medical practice. The preparation of a single or unit dosage form however, does not imply that the dosage form is administered once per day or once per course of therapy. A unit dosage form may comprise, consist essentially of, or consist of a single daily dose or a fractional subâdose wherein several unit dosage forms are to be stered over the course of a day in order to te a daily dose. According to the present sure, a unit dosage form can be given more or less often that once daily, and can be administered more than once during a course of therapy. Such dosage forms can be stered in any manner consistent with their formulation, including orally, ly, nasally, and/or parenterally. While single administrations are specifically contemplated, the compositions administered according to the methods described herein may also be administered as a continuous infusion or via an implantable infusion pump.
The methods as described herein may utilize any of a variety of suitable forms for a variety of routes for administration, for example, for oral, nasal, or rectal routes of administration. Depending upon the particular route of administration desired, a variety of pharmaceuticallyâacceptable rs wellâknown in the art can be used. ceuticallyâacceptable carriers include, for example, solid or liquid fillers, diluents, hydrotropes, surfaceâactive agents, and encapsulating nces. Optional pharmaceuticallyâactive materials can be included, which do not substantially interfere with the activity of the one or more compounds in the formulation. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound. ques and compositions for making dosage forms useful in the methods described herein are described in the following references, all incorporated by nce herein: Modern Pharmaceutics, 4th Ed., rs 9 and 10 (Banker & Rhodes, s, 2002); Lieberman er al., Pharmaceutical Dosage Forms: Tablets (1989); and Ansel, Introduction to ceutical Dosage Forms 8th Edition (2004).
Various oral dosage forms can be used, including such solid forms as tablets, capsules, granules and/or bulk powders. Tablets can be compressed, tablet triturates, entericâcoated, coated, filmâcoated, or multipleâcompressed, ning suitable binders, lubricants, diluents, disintegrating agents, coloring agents, ïŹavoring agents, ïŹowâ inducing agents, and/or melting agents. Liquid oral dosage forms include aqueous solutions, emulsions, sions, solutions and/or suspensions reconstituted from nonâ effervescent granules, and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifying , suspending , diluents, ners, melting agents, coloring agents and/or ng agents, or any combination thereof.
The pharmaceuticallyâacceptable carriers suitable for the preparation of unit dosage forms for peroral administration are wellâknown in the art. Tablets typically comprise conventional pharmaceuticallyâcompatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and/or cellulose; binders such as starch, gelatin and/or sucrose; disintegrants such as starch, alginic acid and/or croscarmelose; lubricants such as magnesium stearate, stearic acid, microcrystalline ose, ymethyl cellulose, and/or talc. Tablets may also comprise solubilizers or emulsifiers, such as poloxamers, hor/KolliphorÂź/LutrolÂź, or methylcellulose, hydroxypropylmethylâcellulose, or others as are known in the art, or any combination thereof. Glidants such as silicon dioxide can be used to improve ïŹow characteristics of the powder e. Coloring agents, such as the FD&C dyes, can be added for appearance. Sweeteners and ng agents, such as ame, saccharin, menthol, peppermint, and/or fruit ïŹavors, or any combination f, are useful adjuvants for chewable tablets. Capsules typically se one or more solid diluents disclosed above. The selection of carrier components depends on secondary considerations like taste, cost, and shelf stability, which can be readily made by a person skilled in the art. l (PO) compositions also include liquid solutions, emulsions, or suspensions. The pharmaceuticallyâacceptable carriers suitable for preparation of such compositions are well known in the art. Typical components of carriers for syrups, elixirs, emulsions and/or suspensions include ethanol, glycerol, propylene glycol, hylene glycol, liquid sucrose, sorbitol and/or water. For a suspension, typical suspending agents include methyl cellulose, sodium carboxymethyl cellulose, AVICEL RCâ59l, tragacanth and/or sodium alginate; typical wetting agents include lecithin and/or polysorbate 80; and typical preservatives include methyl paraben and/or sodium benzoate, or any combination thereof. Peroral liquid compositions may also contain one or more components such as sweeteners, ïŹavoring agents and/or colorants, as disclosed above.
Peroral compositions can also be in the form of uffs, such as candy, an applesauce, a yogurt, a soft pudding, a gelatin foodstuff, a juice, milk, a soy or nut beverage, a thickened beverage, or a cheese, or any combination thereof.
Such compositions may also be coated by conventional methods, typically with pH or timeâdependent coatings, such that the subject one or more compounds are released in the gastrointestinal tract in the ty of the desired ation, or at various times to extend the desired action. ary dosage forms for release in the gastrointestinal tract may incorporate one or more of cellulose acetate phthalate, polyvinyl acetate phthalate, ypropyl methyl cellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and/or shellac, or other excipients known to those of skill in the art, or any combination f. According to some embodiments, the compositions to be administered according to the methods described herein are formulated for release in the gastrointestinal tract.
According to some embodiments, the compositions to be administered according to the methods described herein are formulated for release in the lower gastrointestinal tract. In some ments, the compositions are ed as enteric coated capsules, tablets, soft gels; or intrinsically enteric capsules.
The actual unit dose of the compositions described herein depends on the one or more compounds in the formulation. In some embodiments, the amount of each compound in the formulation can be from 5 mg/kg to 500 mg/kg or more of body weight per day, from 10 mg/kg or less to 70 mg/kg, from 50 mg/kg to 80 mg/kg of body weight per day, from 70 mg/kg to 120 mg/kg of body weight per day, from 100 mg/kg to 300 mg/kg of body weight per day, or from 250 mg/kg to 500 mg/kg of body weight per day.
In some ments, the dose can be less than 100 mg/kg, 500 mg/kg, 300 mg/kg, 200 mg/kg, 150 mg/kg, 100 mg/kg, 50 mg/kg, 40 mg/kg, 30 mg/kg, 25 mg/kg, 20 mg/kg, 10 mg/kg, 7.5 mg/kg, 6 mg/kg, 5 mg/kg, 4 mg/kg, 3 mg/kg, 2.5 mg/kg, or 1 mg/kg of body weight per day or an amount that is within a range defined by any two of the aforementioned amounts. In some ments, the actual unit dose is 5, 10, 25, 50, 75, 100, 150, or 200 mg/kg of body weight per day or an amount that is within a range defined by any two of the aforementioned amounts. Thus, for administration to a 70 kg person, for example, the dosage range is from 350 mg to 750 mg, from 500 mg to l g, from 750 mg to 2 g, from 1 g to 5 g, from 2.5 g to 6g, from 4g to 10 g, from 8 g to 20 g, from 15 g to 35g, or from lg or less to 35 g or more, or an amount that is within a range defined by any two of the aforementioned amounts. In some embodiments, the actual unit dose is 6 g. In some embodiments the actual unit dose is 10 g. In some embodiments, the actual unit dose is 35 g. In some embodiments, the actual unit dose is l g or less but not zero. In some ments, the actual unit dose is 10 g or less but not zero. In some embodiments, the actual unit dose is 35 mg or less but not zero.
"Loading dose," as used herein refers to an initial dose of a compound which is higher than subsequent doses.
"Maintenance dose," as used herein refers to a subsequent dose that follows a loading dose, and occurs later in time than a loading dose. One of ordinary skill in the art will be aware that the dosage form or mode of administration of a maintenance dose can be different from that used for the g dose. In any of the embodiments disclosed herein, a maintenance dose may comprise administration of the unit dosage form on any dosing schedule contemplated herein, including but not limited to, monthly or multiple times per month, biweekly or multiple times each two weeks, weekly or multiple times per week, daily or multiple times per day. It is contemplated within the present disclosure that dosing holidays can be incorporated into the dosing period of the maintenance dose.
Such dosing holidays may occur immediately after the stration of the loading dose or at any time during the period of administration of the maintenance dose. As used herein, the period of administration of the maintenance dose can be referred to as the enance phase" of the treatment period.
"Mode of administration" as used herein refers to the avenue by which one or more compounds are administered to a subject. As used herein, "mode of administration" comprises the dosage form (for e, a tablet, powder, dissolved , suspension, emulsion, etc.) and mechanism by which the dosage form is applied to the subject (for example, orally, such as by a pill, dissolved liquid, oral suspension). As used herein, "mode of administration" also comprises the dose, dose amount, and dosing le by which a compound is administered to a subject.
In some ments, the compositions to be administered according to the methods of the present disclosure are provided with, or mixed into, a foodstuff, beverage, or other ingestible item. In some embodiments, said beverage, foodstuff, or other ingestible item may se, consist essentially of, or consist of one or more of a candy, an applesauce, a yogurt, a soft pudding, a gelatin foodstuff, a juice, milk, a soy or nut ge, a thickened beverage, or a cheese, or any combination thereof. One of ordinary skill will readily recognize that the combination of the compositions to be administered according to the methods of the disclosure can be combined with any suitable food or beverage to facilitate ingestion of the compositions.
Because levels of some metabolites will be expected to ïŹuctuate in response to external stimuli, the methods according to the present disclosure contemplate varying or controlling the timing of stration of the itions described herein, in order to enhance the effectiveness of the treatment, for example, by optimizing the l of harmful metabolites or limiting the removal of helpful metabolites, in such a manner as to maintain both the somatic and the ial health of the subject. In some embodiments, the compositions to be administered according to the methods of the present disclosure can be administered with food, such as concurrently with a meal or other ion of a foodstuff. In some further embodiments, the compositions to be administered according to the methods of the present disclosure can be administered immediately before or immediately after a meal or other ingestion of a foodstuff. In some further embodiments, the compositions to be administered according to the methods of the present disclosure can be administered within 1â5 s, within 3â10 s, within 6â15 minutes, within â20 minutes, within 15â30 minutes, within 20â45 minutes, or within one hour before or after a meal or other ingestion of a foodstuff. In some embodiments, the compositions to be administered ing to the methods of the present disclosure can be administered t food, such as between 1â3 hours, between 2â5 hours, between 4â8 hours, between 6â12 hours, n 9â18 hours, between 12â24 hours, or more than 24 hours before or after a meal or other ingestion of a foodstuff.
As used herein, "duration of the treatment" refers to the time cing with administration of the first dose and concluding with the administration of the final dose, such length of time being ined by one of ordinary skill in the art of treating neurological disorders or disorders implicating intestinal hyperpermeability (leaky gut), with reference to the symptoms and health of the subject being treated therefor. Such duration can be determined with reference to periodic, sporadic, or g monitoring of the levels of the lites as disclosed herein or as known to one of skill in the art of treating neurological disorders and disorders implicating intestinal hyperpermeability (leaky gut).
As used herein, "dosing holiday" refers to a period of 24 hours or more during which either no dose is administered to the subject, or a d dose is administered to the subject. As used herein, "reduced dose" refers to a dose that is less than the total daily dose to be administered to a subject.
According to the s disclosed herein, a reduction in serum metabolites is achieved by modulating the dosing schedule such that subjects experience periodic partial or full reductions in dosing for fixed amounts of time, followed by a resumption of dosing. In some embodiments, dosages are administered daily for between one and thirty days, followed by a dosing holiday lasting for between one and thirty days. In some embodiments, during the dosing y, no dose is stered. In some further embodiments, the composition of the present disclosure is allowed to clear completely from the subjectâs body prior to administration of the next dose. In some other embodiments, during the dosing holiday, a dose less than the usual daily dose is administered. In some r embodiments, an amount of the administered composition less than the therapeutically ive amount is allowed to remain within the subject during the dosing holiday. In some further embodiments, an amount of the administered composition sufficient to maintain therapeutic levels in the affected tissues is allowed to remain within the subject. ing to the present disclosure, the dosing schedule can be varied so as to attain the desired therapeutic . In each of the embodiments as disclosed herein, variations in dosing schedule can be repeated throughout the duration of the therapeutic protocol being administered. In each of the embodiments as disclosed herein, the first dosage can be higher, lower, or the same as the dosages following the first dosage. In each of the embodiments sed herein, a loading dose may precede the disclosed dosing regimen, and a dosing holiday may or may not follow the stration of the g dose.
In some ments the methods of the present disclosure comprise administration of the one or more compositions provided herein daily or less frequently than daily, such as every second day, every third day, every fourth day, every fifth day, every sixth day, or every seventh day or for a time period that is within a range defined by any two of the aforementioned times.
The methods of the present disclosure can be used in the ent, prevention, and/or amelioration of one or more neurological disorders including autism spectrum disorder, schizophrenia, an anxiety disorder, depression, Parkinson's Disease, Rett me, Fragile X Syndrome, Tuberous Sclerosis, Multiple Sclerosis, Alzheimerâs Disease, Angelman Syndrome, Williams Syndrome, amyotrophic lateral sclerosis, leukodystrophies including Alexander Syndrome, alphaâsynucleinopathies including Lewy Body Dementia, incidental Lewy body disease, Lewy body variant of Alzheimerâs e, multiple system y, pure mic e, or any combination thereof.
Said disorders may include behavioral symptoms as are known in the art of clinical diagnosis and ent of neurological disorders such as communicative symptoms, cognitive disorders, stereotyped behaviors, sensorimotor issues, clinical irritability, and/or anxietyâlike behaviors in addition to physical symptoms as are known in the art of diagnosis and treatment of neurological disorders such as tremors, paralysis, esia, and /or gastrointestinal symptoms such as intestinal hyperpermeability (leaky gut).
Accordingly, such al and/or diagnostic evaluations and determinations can be used to identify and/or select one or more subjects for receiving one or more compounds described herein in accordance with the one or more methods provided in this disclosure.
The methods of the present disclosure may, in some embodiments, include monitoring of the behavioral, physical, and/or gastrointestinal symptoms as are known in the art of diagnosis and treatment of neurological disorders. In some embodiments, the methods according to the present sure incorporate monitoring changes in the behavior of a subject. In some further embodiments, the methods according to the present sure incorporate monitoring the subject for behavioral symptoms as are known to be related to autism spectrum disorder, schizophrenia, an anxiety disorder, depression, Parkinson's Disease, Rett Syndrome, Fragile X Syndrome, Tuberous Sclerosis, Multiple Sclerosis, Alzheimerâs Disease, an Syndrome, Williams Syndrome, amyotrophic lateral sclerosis, leukodystrophies including Alexander Syndrome, alphaâsynucleinopathies including Lewy Body Dementia, incidental Lewy body disease, Lewy body variant of Alzheimerâs disease, multiple system atrophy, pure autonomic e, or any combination thereof. In some embodiments, the red behavioral symptoms do not se clinical anxiety. In some further embodiments, the methods according to the present disclosure incorporate monitoring the subject for repetitive behaviors, communicative symptoms, ive disorders, stereotyped behaviors, attachment to physical objects, aphasia, obsessive ors, unusual or opriate body language, gestures, and/or facial expressions and/ or sensorimotor issues, lack of interest in other people, lack of empathy, difficulty grasping nonverbal cues, touch aversion, difficulty in socialization, speech delays, al vocal tone or pitch, vocal repetition, perseveration, conversational difficulty, difficulty communicating needs or desires, inability to understand simple ents or questions, difficulties in processing language t, obsessive attachment to unusual objects, upation, intolerance of changes in routine or environment, ness, abnormal posture, odd ways of moving, fascination with particular objects, hyperâ or hypoâreactivity to sensory input, clinical irritability or any combination thereof. Again, such al and/or diagnostic evaluations and determinations can be used to identify and/or select one or more subjects for ing one or more compounds described herein in ance with the one or more methods provided in this disclosure. In additional embodiments, the methods may incorporate monitoring the t for tremors, paralysis, and/or dyskinesia, or other symptoms known to those in the art of diagnosing and treating neurological disorders, or any combination thereof. In some embodiments, the methods of the t disclosure may include monitoring of microbial and/or intestinal metabolites as disclosed herein or as known to those of skill in the art. According to the s of the present disclosure, said metabolites can be monitored in the gut, feces, urine, blood, saliva, cerebrospinal fluid, and/or synovial ïŹuid of a subject. The methods of the present disclosure contemplate the monitoring of said metabolites in any tissue or ïŹuid obtainable from a subject during the course of treatment. Again, such clinical and/or stic evaluations and determinations can be used to identify and/or select one or more ts for receiving one or more compounds described herein in accordance with the one or more methods provided in this disclosure.
In some embodiments, the compositions are administered at any time following the onset of one or more of the aforementioned symptoms of a neurological er associated with inal hyperpermeability (leaky gut) and/or intestinal dysbiosis. In some embodiments, the compositions according to the methods described herein are administered prior to the onset of symptoms of said disorder or disorders. In some embodiments, the compositions according to the methods described herein are administered concurrently with or after the onset of symptoms of said disorder or disorders.
The methods described herein are further illustrated by the following examples.
Example 1 Establishment of 4EPâproducing microbiota and administration of ABâ2004 The effect of 4EP production by the gastrointestinal microbiota was investigated using gnotobiotic mice that were diâcolonized with strains engineered to differ solely in their capacity to produce 4EP, which is converted to 4EPS by the host. The effect of an ABâ2004 preparation that sequesters 4âEP, its derivative 4âEPS and other toxic microbial metabolites, was investigated by formulating the ABâ2004 into mouse food and administering it in parallel with a control diet that did not n 4 but was otherwise cal. Impact of 4EP tion by the iota and 4 administration was determined via assessments of repetitive, social and anxietyâlike behaviors that represent core and nonâcore symptoms of autism spectrum disorders (ASD).
To produce the engineered strains, the Bacteroides ovams gene for pâcoumaric acid production was cloned in tandem with the us subtilis gene for phenolic acid decarboxylase into the B. ovams chromosome to produce 4âvinylphenol. Lactobacillus plantarum converts 4âvinylphenol produced by the engineered B. ovams strain to 4âEP.
To produce a pair of otherwise cal strains that is incapable of 4EP production, a lossâofâfunction mutation was introduced into the B. ovams strain, resulting in elimination of 4âvinylphenol production and consequently 4âEP production by L. plantarum.
At the age of 5 weeks, mice were placed on a diet that contained 8% w/w of an ABâ2004 preparation (ASTâlZO, Kureha Corporation, Japan), or an otherwise identical diet that did not contain ABâ2004. Colonization of mice was quantified by plating dilutions of fecal nates on solid media, and the two pairs of strains were confirmed to colonize mice to similar levels, as similar levels of colony forming units per mL fecal nate were produced in the assay (Figure 2). Table 1 describes the identifiers used for groups of mice in figure labels in this section.
Table l. Descri-tions of Mouse Grou- Labels in Fiures Mouse Group ID Microbiota 4EPâ Control Does not produce 4EP Control diet 4EP+ Control Produces 4EP Control diet 4EPâ ABâ2004 Does not produce 4EP Contains 8% ABâ2004 4EP+ ABâ2004 Produces 4EP Contains 8% 4 Marble Burying A marble burying test was used to assess repetitive or, which is a core symptom of ASD. In the assay as described by Malkova er al. (Behav Immun. 26(4):607â 16 (2012)), marbles are placed on top of bedding in a cage, a test mouse is placed in the cage, and the number of marbles buried by the mouse during the test period is measured.
As shown in Figure 3(a), in the assay, mice on control diet that were diâcolonized with 4â EP producing microbes buried significantly more marbles than mice on control diet that had been diâcolonized with microbes that did not produce 4âEP, thereby demonstrating repetitive behavior due to 4EP production by the gut microbiota. Administration of ABâ 2004 normalized this repetitive behavior in the assay: mice with 4âEP producing microbiota on the ABâ2004 diet burying significantly fewer s than mice with 4âEP producing microbiota on control diet. The data indicate that administration of materials that sequester 4âEP, 4âEPS and/or other toxic microbial metabolites can be beneficial for reducing repetitive behaviors, one of the core symptoms of ASD.
Elevated Plus Maze The elevated plus maze (EPM) test of exploratory behavior was used to assess l locomotion and yâlike behavior. Mice were allowed 5 minutes to explore an elevated plus maze sed of two open arms and two closed arms that extend from a common central platform. A small raised lip around the edges of the open arms helped t mice from slipping off. An overhead video camera was used to record the session, and Ethovision re (Noldus Information Technology, Sacramento, CA) was used to e mouse nts. Time spent in closed, relatively protected portions of the maze versus time spent exploring open, vely exposed portions of the maze is interpreted as a measurement of anxiety. As shown in Figure 3(b), in the assay, mice with 4âEP producing microbiota on control diet spent less time than mice on control diet with microbiota that does not produce 4âEP in open portions of the EPM versus closed portions of the EPM, thereby demonstrating anxietyâlike or due to production of 4EP by the intestinal iota. Administration of an ABâ2004 preparation normalized these anxietyâlike behaviors in the assay, as mice with 4âEP producing microbiota on ABâ 2004 diet spent significantly more time in open versus closed portions of the EPM than mice with 4âEP producing microbiota mice on control diet that lacks ABâ2004. Anxiety is a common nonâcore symptom of ASD, and these indicate that administration of sequestrants of 4âEP, 4âEPS and/or other toxic microbial metabolites can be beneficial in reducing anxiety symptoms in some ASD patients.
Open Field The open field test of exploratory behavior was used to assess l tion and anxietyâlike behavior. For openâfield testing, mice were allowed to explore a 50 x 50âcm white Plexiglas box for 10 min. An overhead video camera was used to record the session, and Ethovision software (Noldus Information logy, ento, CA) was used to analyze the distance traveled, and the number of entries and duration of time spent in the center arena al , 17 x 17 cm) versus the wall area of the box. Mice on control diet that had been colonized with 4âEP producing microbiota exhibited an anxietyâ like phenotype in the assay, ng the wall area with greater frequency and spending more time in the wall area compared to mice on the control diet that had been colonized with microbiota that did not produce 4âEP. In the assay, the amount of time that mice that had been colonized with 4âEP producing microbiota on ABâ2004 diet spent in the wall area (Figure 4(B)) and the frequency with which they entered the wall area (Figure 4(A)) were r to mice that had been colonized with microbiota that do not produce 4âEP, suggesting normalization of this behavior by ABâ2004. Total distance moved (Figure 4(C)) in the open field test was similar for all groups, suggesting that differences in exploration of open versus closed parts of the field are not due to differences in the distance that the mice moved during the test. Consistent with the EPM data, these data e additional evidence that administration of materials that sequester 4âEP, its derivative 4âEPS and/or other toxic microbial metabolites can be beneficial in alleviating symptoms of anxiety in ASD patients who suffer from them.
Direct Social Interaction A threeâchambered social approach test was used to measure direct social interaction. The test mouse was placed in the center chamber of three adjacent chambers, with a novel object in an adjacent terminal chamber and an unfamiliar mouse in the other adjacent al chamber. The test mouse was habituated in the apparatus for 10 minutes prior to initiation of scoring. The test mouse was able to pass through openings from the center chamber into each of the adjacent chambers. The test was recorded by video, and the time spent by the test mouse in the chamber with the liar mouse was scored manually. A higher amount of time spent with the unfamiliar mouse is an indicator of increased ility, while a lower amount of time spent with the unfamiliar mouse is an indicator of decreased sociability, consistent with the social deficits that are a core symptom of Autism Spectrum Disorders.
As shown in Figure 5, in the threeâchamber test of social interaction, male mice diâcolonized with 4EPâproducing microbiota spent significantly less time in the chamber with another mouse than male mice diâcolonized with microbes that do not produce 4EP.
In the assay, there was a trend for improvement of this social deficit by treatment with an ABâ2004 preparation (p=0.107l). These data indicate that stration of materials such as ABâ2004 that sequester 4EP, its derivative, 4EPS, and other toxic microbiallyâ derived lites to patients with ASD can be beneficial to e core symptoms of ASD, such as social ts.
Example 2 Removal of microbial metabolites by sequestrant materials A 50 mg/mL stock solution of a single microbial metabolite was prepared in ylsulfoxide (DMSO) and serially diluted (2:1) in DMSO to create standard solutions of 50, 25, 12.5, 6.25, 3.125, 1.56 and 0.78 mg/mL. Each DMSO standard solution (10 uL) was diluted into deionized water (990 uL) to create standard calibration samples of 0.5, 0.25, 0.125, 0.06, 0.03, 0.015, 0.078 mg/mL aqueous solutions (1% DMSO). A blank sample was prepared by adding 10 uL DMSO to 990 uL distilled water and the UVâabsorbance of each aqueous standard solution was measured at a single wavelength using a Thermo ific NanoDropTM spectrophotometer to identify the linear range of absorbance and generate a calibration curve.
A 0.5 mg/mL solution of a single microbial metabolite was prepared in zed water by adding 100 uL of 50 mg/mL DMSO stock solution to 9.9 mL deionized water.
Next, 50 mg/mL of one of a series of trant material being tested was added and the solution was stirred at room temperature. The resulting mixture was sampled over a time course from 0 to ÂŁ4 hours. At each time point, approximately 1 mL of sequestrant mixture was taken up by syringe and passed through a nylon syringe filter (0.2um). Each sample was appropriately diluted with deionized water and either transferred to a cuvette for analysis using a Thermo ScientificTM NanoDrop (Fisher Scientific, Waltham, MA) or transferred to a 96âwell clear bottom plate for is using a Spectramax i3x (Molecular Devices, San Jose, CA).
The absorbance of 4âEP by various representative sequestrant materials was conducted according to the general protocol. The UVâabsorbance of each sample was measured at 270 nm by spectrophotometry. The % ing of 4âEP following treatment with representative adsorbent materials at 50 mg/mL for 2 hours is reported in Table 2.
The following gs apply: "++++" refers to 90% remaining or no absorption observed. The zeolite used was clinoptilolite, with the general stoichiometry of (Na,K,Ca)2_3A13(Al,Si)ZSi13036-l2HzO; bentonite preparation was produced from Bentonite B.P. (Halewood Chemicals, UK); activated charcoal preparation was produced from 260 mg Activated Charcoal Dietary Supplement capsules (Natureâs Way, Green Bay, WI), and the ABâ2004 preparation was produced from 0 (Kureha Corporation, Japan).
Table 2: tion of 4âEP % in %remaining +++ 3 cellulose acetate propionate +++ 17â7° Mn~15,000 cellulose acetate nate + 20% AB-2004 ++++ <1% Activated charcoal ++++ <1% Example 3 The removal of 4âEPS from test solutions by various representative sequestrant materials was conducted according to the general protocol given in Example 2 with the UVâabsorbance of each sample measured at 265 nm using spectrophotometry. The % ing of 4âEPS following provision of representative adsorbent als at 50 mg/mL for 2 hours is reported in Table 3.
Table 3: Abso ntion of 4âeth l-hen l sulfate % Remaining 00 2 hours cellulose acetate propionate 85° 0 ABâ2004 00000000 00000000 Example 4 The removal of pâcresol from test solutions by various representative sequestrant materials was conducted according to the general protocol given in Example 2 with the UVâabsorbance of each sample measured at 260 nm using spectrophotometry. The % remaining of pâcresol following provision of representative adsorbent materials at 50 mg/mL for 2 hours is reported in Table 4.
Table 4: Absorption of pâcresol cellulose e propionate Example 5 The l of pâcresyl sulfate from test solutions by various representative sequestrant materials was conducted according to the l protocol given in Example 2 with the UVâabsorbance of each sample measured at 260 nm using spectrophotometry.
The % remaining of yl sulfate following treatment with representative adsorbent materials at 50 mg/mL for 2 hours is ed in Table 5.
Table 5: Absorption of pâcresyl sulfate cellulose acetate propionate MnN75â000 Example 6 The l of indole from test solutions by various representative sequestrant materials was conducted according to the general ol given in Example 2 with the UVâabsorbance of each sample measured at 278 nm using spectrophotometry. The % remaining of indole following provision of representative adsorbent materials at 50 mg/mL for 2 hours is reported in Table 6.
Table 6: Absorption of indole Material % Remaining @ 2 hours ose acetate propionate +++ 13y° Mn~75 000 AB-2004 ++++ <1% Example 7 The removal of 3âindoxyl sulfate from test solutions by various entative sequestrant materials was conducted according to the general protocol given in Example 2 with the orbance of each sample measured at 260 nm using spectrophotometry.
The % remaining of 3âindoxyl sulfate following treatment with representative adsorbent materials at 50 mg/mL for 2 hours is reported in Table 7.
Table 7: Absorption of 3âindoxyl sulfate Material % Remaining @ 2 hours % remaining zeolite NA 100% bentonite NA 100% cellulose e propionate + 73y° Mn~75 000 ABâ2004 ++++ 3% Example 8 The removal of 4âhydroxyphenylacetic acid from test solutions by various representative sequestrant materials was conducted ing to the general protocol given in e 2 with the UVâabsorbance of each sample measured at 278 nm using spectrophotometry. The % ing of tyrosine ing treatment with representative adsorbent materials at 50 mg/mL for 2 hours is reported in Table 8.
Table 8: Absorption of 4âhydroxyphenylacetic acid m% Remaining @ 2 hours % remaining ose acetate proplonate + 86% Mn~75,000 Example 9 The removal of 2âhydroxyâ2(4âhydroxyphenyl)acetic acid from test solutions by various representative sequestrant materials was conducted according to the general protocol given in Example 2 with the UVâabsorbance of each sample measured at 278 nm using spectrophotometry. The % remaining of 2âhydroxyâ2(4âhydroxyphenyl)acetic acid following treatment with representative adsorbent materials at 50 mg/mL for 2 hours is reported in Table 9.
Table 9: Absorption of 2âhydroxyâ2(4âhydroxyphenyl)acetic acid Material % Remaining @ 2 hours % remaining zeolite NA 100% bentonite NA 100% cellulose acetate propionate + 8" AB-2004 <1% Example 10 The l of Lâhomocitrulline from test solutions by various representative trant materials was conducted according to the general protocol given in Example 2 with the UVâabsorbance of each sample measured at 274 nm using spectrophotometry.
The % remaining of Lâhomocitrulline following treatment with representative adsorbent materials at 50 mg/mL for 2 hours is reported in Table 10.
Table 10: Absorption of Lâhomocitrulline Material % Remaining @ 2 hours % remaining zeolite NA 90% bentonite NA 91% cellulose acetate propionate NA 94â7° Mn~75,000 ABâ2004 ++++ <1% Example ll Indoxyl sulfate, yl sulfate, and 4âethylphenyl sulfate, respectively, were separately dissolved in phosphate buffer at pH 6.8 and exposed to ABâ2004 with stirring for various lengths of time. At various time points, samples were awn and assayed for the presence of the respective compound ed "toxins" below), and the amount of each compound removed from solution was calculated. Results are shown below in Table ll, where "Activated Charcoal" refers to an 4 preparation.
"V \tâ..âssâoex} These results indicate that maximal absorption occurs in less than four hours of exposure for each nd when exposed to an ABâ2004 preparation.
Example 12 Indoxyl sulfate, pâcresyl sulfate, and 4âEP, were simultaneously dissolved in phosphate buffer at pH 6.8 to create a simulated metabolite mixture and d to ABâ 2004 with stirring for various lengths of time. At various time points, samples were withdrawn and assayed for the presence of the respective compound (labeled s" below), and the amount of each compound removed from solution was calculated.
Results are shown below in Table 12, where ated Charcoal" refers to an ABâ2004 preparation.
These s indicate that maximal absorption occurs in less than four hours of exposure even for compounds in mixed solutions when exposed to an ABâ2004 preparation.
Example 13 4âethylphenyl sulfate, was dissolved in phosphate buffer at pH 6.8 and exposed to ABâ2004, cellulose acetate propionate (MW 15K and 75K), bentonite, and clinoptilolite zeolite with stirring for various lengths of time. At various time points, samples were withdrawn and assayed for the presence of the tive compound, and the percentage of each compound removed from solution was calculated. Results are shown in Figure 6.
These results provide evidence that cellulose based polymeric als are effective sequestrants of the metabolite 4âEP.
Example 14 Removal of microbial metabolites in fecal slum supernatant by sequestrant To determine the capacity of ABâ2004, bentonite, e, cellulose acetate propionate (Mn ~15,000) and activated charcoal to adsorb the toxins 4âethylphenol, pâ cresol and 3âindoxyl sulfate from a x mixture of metabolites similar to those found in the lumen of the human colon, an ex vivo assay was performed using human stool. A freshly ted stool was maintained at or below 4° C In an anaerobic chamber (ASâ 580, Anaerobe Systems, Morgan Hill, CA) with an atmosphere of 5% carbon dioxide, 5% hydrogen and balance en, the stool was suspended in iceâcold ate buffered saline by pipetting to achieve 20% w/v fecal slurry, solids were d to settle, and the supernatant was erred to conical tubes on ice prior to transfer to an aerobic atmosphere and â80°C. All subsequent steps were med cally. Frozen aliquots were thawed on ice, centrifuged at 21,000 x g for 3 minutes, and supernatant was transferred to fresh tubes and diluted with an equal volume of ice cold phosphate buffered saline. 4âethylphenol, pâcresol and 3âindoxyl sulfate were prepared in dimethyl sulfoxide at 25 mg/mL and added to separate aliquots of the fecal slurry supernatant to a final concentration of 2 mg/mL. Spiked fecal slurry supernatants were added to the sequestrant als consisting of an ABâ2004 preparation, bentonite, zeolite, cellulose acetate propionate (Mn~15,000) and activated charcoal for 35â59 mg/mL final of the sequestrant materials, with the exception that activated charcoal was tested at 98 mg/mL versus pâ cresol. The mixtures were incubated with vigorous mixing in conical tubes at 750 rpm at ° C for 4 hours and centrifuged at 21,000 x g for 3 minutes. The supernatant was transferred to a 96âwell plate and diluted 10âfold in ate buffered saline prior to determining the tration of the metabolites by measuring tion at 278 nm with a spectrophotometer (Spectramax i3x, Molecular Devices, San Jose, CA).
A standard curve was generated for each of the toxins by adding them to the fecal slurry atant at 4, 2, l, 0.5 and 0.25 mg/mL final, diluting them 10âfold in phosphate buffered saline, and measuring absorption at 278 nm. The concentration of spiked 4â ethylphenol, pâcresol and 3âindoxyl sulfate in samples was determined by interpolation from the standard curves using GraphPad Prism 7 (GraphPad, La Jolla, CA). The percentage of spiked toxin that was removed by sequestrant was calculated by dividing the interpolated value by the interpolated value of a spiked control sample that was not treated with a sequestrant material and lying by 100. The percentage of spiked toxin removed by each sequestrant is shown in Table 13.
Percentage Spiked Toxin Remaining CeHulose Acetate Propionat e ABâ Bentonh e d 2004 e hïŹn~15,000 Charcoal %Remmnmg ++++ ++ +++ ++++ Range 4-Ethylphenol 99% >99% Key to Tables 13 and As seen in Table 13, the number of toxins adsorbed and the extent of adsorption of each toxin varied across materials tested in the assay. ABâ2004 and activated al each adsorbed >90% of the spiked 4âethylphenol, 3âindoxyl sulfate and pâcresol in the assay, while ose acetate propionate adsorbed 65â90% of spiked lphenol and to a 35â65% of pâcresol, but less than 10% of spiked 3âindoxyl sulfate. Bentonite adsorbed â65% of spiked 4âethylphenol and 10â35% of spiked pâcresol in the assay, and To ine the capacity of ABâ2004, bentonite, zeolite and cellulose acetate propionate (Mn ~l5,000) to adsorb the toxins 4âethylphenyl sulfate and pâcresyl sulfate from a complex mixture of metabolites similar to those found in the lumen of the human colon, an ex vivo assay was performed using human stool. A freshly collected stool was maintained at or below 4° C in an anaerobic chamber (ASâ580, Anaerobe Systems, Morgan Hill, CA) with an atmosphere of 5% carbon e, 5% hydrogen and balance nitrogen, the stool was suspended in iceâcold phosphate buffered saline by pipetting to e 20% w/v fecal slurry, solids were allowed to settle, and the atant was transferred to conical tubes on ice prior to transfer to an aerobic here and â80°C.
All subsequent steps were performed aerobically. Frozen aliquots were thawed on ice, centrifuged at 21,000 x g for 3 minutes, and supernatant was transferred to fresh tubes. 4â ethylphenyl sulfate and pâcresyl sulfate were prepared in dimethyl sulfoxide at 25 mg/mL and added to separate aliquots of the fecal slurry supernatant to a final concentration of 0.75 mg/mL, in triplicate. The spiked fecal slurry supematants were added to the sequestrant materials consisting of an ABâ2004 preparation, bentonite, zeolite, and cellulose acetate propionate (Mn~75,000) to e 12 mg/mL final of the sequestrant materials. The mixtures were incubated with us mixing in conical tubes at 1700 rpm at room temperature for 1 hour and fuged at 12,000 x g for 1 minute. The supernatant was transferred to fresh conical tubes and frozen at â80°C prior to quantification of lphenyl sulfate and pâcresyl sulfate by LCâMS/MS analysis against a surrogate matrix curve es River, Worcester, MA). Results are shown in Table 14.
Percent Toxin Remaining Material 4âEthylphenyl pâCresyl Sulfate Sulfate AB-2004 ++ +++ Cellulose Acetate Propionate Mn ~75,000 Table 14. Percent 4âethylphenyl sulfate and pâcresyl sulfate remaining following 1 hour incubation with various materials As seen in Table 14, ABâ2004 demonstrated the greatest ty for 4âethylphenyl e and pâcresyl sulfate of any of the tested materials. Cellulose Acetate Propionate ed 7â35% of pâcresyl sulfate but less than 7% of 4âethyl phenyl sulfate in the assay.
Bentonite and e adsorbed less than 7% of 4âethylphenyl sulfate and yl e in the assay. Thus, the tested materials demonstrated a range of ties for 4â ethylphenyl sulfate and pâcresyl sulfate within the ex vivo assay, which recapitulates some of the diversity and composition of metabolites found in the human gut.
Example 15 Modeling MIA in mice by injecting pregnant dams with the viral doubleâstranded RNA mimic poly(I:C) yields offspring that exhibit the core communicative, social, and typed impairments relevant to ASD. nt C57BL/6N mice are injected intraperitoneally on day E125 with saline or 20 mg/kg poly(I:C) according to methods described in Smith et al. , J. Neurosci., 27:10695â10702, which is hereby incorporated by reference in its entirety. MIA offspring and control ing are either treated with an effective amount of an ABâ2004 preparation daily for 10 days, or are left untreated for 10 days. Offspring are monitored for levels of 4âEP, 4âEPS, PC, PCS, 4â hydroxyphenylacetate, 2âhydroxyâ2(4âhydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or 3âindoxyl sulfate in blood, urine and feces. Levels of 4âEP, 4âEPS, PC, PCS, 4âhydroxyphenylacetate, 2âhydroxyâ2(4âhydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or 3âindoxyl sulfate are observed to be reduced in ABâ2004 treated MIA offspring relative to untreated MIA offspring. The treated offspring are observed to have levels of 4âEP, 4âEPS, PC, PCS, 3â4âhydroxyphenylacetate, 2âhydroxyâ2(4â hydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or 3âindoxyl sulfate similar to, equivalent to, or reduced as compared to untreated offspring and/or healthy subjects.
MIA offspring and control offspring are also observed for behavioral symptoms of ASD as follows. Open field exploration involves mapping an animalâs movement in an open arena to measure locomotion and anxiety. ted MIA offspring display decreased entries and time spent in the center of the arena, which is indicative of yâ like behavior. Treated MIA offspring and untreated l offspring show commensurate or equivalent amounts of entries and time spent in the center of the arena.
Prepulse inhibition (PPI) measures the y of an animal to inhibit its startle in response to an acoustic tone when it is preceded by a lowerâintensity stimulus.
Deficiencies in PPI are a measure of impaired sensorimotor gating and are ed in l neurodevelopmental disorders, including autism. Untreated MIA offspring exhibit decreased PPI. Treated MIA offspring and untreated control offspring show normal PPI.
The marble burying test measures the propensity of mice to engage repetitively in a natural digging behavior that is not confounded by anxiety. Untreated MIA offspring display increased stereotyped marble burying compared to controls. d MIA offspring and ted control offspring, show normal digging behavior.
Ultrasonic vocalizations are used to measure communication by mice, wherein calls of g types and motifs are produced in different social paradigms. Untreated MIA offspring exhibit deficits in communication, as indicated by d number and duration of ultrasonic zations produced in response to a social encounter. Treated MIA offspring and untreated control offspring show a normal number and duration of ultrasonic vocalizations produced in response to a social ter.
The threeâchamber social test is used to measure ASDârelated impairments in social interaction. Untreated MIA offspring exhibit deficits in both sociability, or preference to interact with a novel mouse over a novel object, and social preference, or preference to ct with an unfamiliar versus a familiar mouse. Treated MIA offspring and untreated control offspring show normal social interaction.
In some experiments, an ant of bacteria comprising one or more of Prevotella species, Bifido bacteria species, Parabacteriodes species, (e.g., P. merdae, P. distasonis), Faecalibacterium species, (e.g., F. itzii), Eubacterium species, Coprococcus species, Lactobacillus reuteri, Lactobacillus sis, Bacteroides caccae, Bacteriodes ovatus, Bacteroides is, Bacteroides vulgatus, and/or Bacteroides otaomicron, or any combination thereof, is administered before, during, or after administration of the sequestrant ition, and the effect of the added bacteria is determined.
Example 16 Fecal s are obtained from human patients undergoing treatment with an ABâ2004 preparation or cholestyramine. For each sample, the ABâ2004 ation or cholestyramine is recovered and compounds eluted from the ABâ2004 or cholestyramine are assayed by GCâMS or TOF mass spectrometry for the presence of any of the microbial metabolites (and hostâgenerated modifications of these metabolites) listed herein. One or more of the microbial metabolites (and/or enerated modifications of these metabolites) described herein is then recovered from the ABâ2004 or cholestyramine, demonstrating that said microbial metabolites (and/or hostâgenerated modifications of these metabolites) are bound or sequestered by ABâ2004 or cholestyramine in humans in vivo. These results Will also trate the therapeutic efficacy of the methods described herein.
MIA ing are generated as described above in Example 15. MIA offspring and control offspring are either treated with ABâ2004 daily for 10 days or left untreated for 10 days. Offspring are monitored for levels of 4âEP, 4âEPS, PC, PCS, 4â hydroxyphenylacetate, 2âhydroxyâ2(4âhydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or 3âindoxyl sulfate in blood, urine and feces. Levels of 4âEP, 4âEPS, PC, PCS, 4âhydroxyphenylacetate, 2âhydroxyâ2(4âhydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or 3âindoxyl sulfate are observed to be reduced in ABâ2004 d MIA offspring ve to untreated MIA ing. The treated offspring are observed to have levels of 4âEP, 4âEPS, PC, PCS, 4âhydroxyphenylacetate, 2âhydroxyâ2(4â hydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or 3âindoxyl sulfate similar to, equivalent to, or reduced as compared to untreated offspring and/or healthy subjects.
MIA offspring and control offspring are also tested for leaky gut symptoms by orally administering oligosaccharides of large size, such as lactulose or high MWâPEGs (1500 or 4000 kD), and/or small sugars such as mannitol, Lârhamnose, or low MWâPEG (400 kD), and/or other indigestible probes such as 51CrâEDTA. Administration of said nds occurs separately from administration of ABâ2004 or other sequestering agent. Urine is collected and monitored for the presence of such molecules, where the presence of the test molecule in the urine is symptomatic of leaky gut. Untreated MIA offspring show significant amounts of lactulose, high MWâPEGs (1500 or 4000 kD), small , ol, Lârhamnose, low MWâPEG (400 kD), 51CrâEDTA and/or other indigestible probes in their urine after oral administration. Treated MIA offspring and untreated control offspring show little or no lactulose, high MWâPEGs (1500 or 4000 kD), small , mannitol, Lârhamnose, low MWâPEG (400 kD), 51CrâEDTA and/or other indigestible probes in their urine after oral administration.
In some experiments, an inoculant of bacteria comprising one or more of Prevotella s, Bifido bacteria species, Parabacteriodes species, (e.g., P. merdae, P. onis), Faecalibacterium species, (e.g., F. prausnitzii), Eubacterium species, Coprococcus species, Lactobacillus reuteri, Lactobacillus rhamnosis, Bacteroides , Bacteriodes , oides fragilis, Bacteroides vulgatus, and/or Bacteroides thetaiotaomicron, or any combination thereof, is administered before, during, or after administration of the sequestrant composition, and the effect of the added bacteria is determined.
Example 18 CNTNAPZ'I' or Shank3'l' mice provide genetic models of autismâlike behaviors.
See, e.g., Welberg et al. (2011), Nature Rev. Neurosci., 12:615 and Silverman et al. (2010), Nature Rev. Neurosci. 11:490â502, each of which is hereby incorporated by reference in its entirety. CNTNAPZ'l', Shank3'l' or cally unaltered (control) mice are either treated with ABâ2004 or other sequestering agent daily for 10 days or left untreated for 10 days. Mice are monitored for levels of 4âEP, 4âEPS, PC, PCS, 4â yphenylacetate, 2âhydroxyâ2(4âhydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or 3âindoxyl sulfate in blood and feces. Levels of 4âEP, 4âEPS, PC, PCS, 4â hydroxyphenylacetate, 2âhydroxyâ2(4âhydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or 3âindoxyl sulfate are ed to be reduced in ABâ2004 treated CNTNAPZ'I' or Shank3â/â mice relative to untreated Z'I' or Shank3'l' mice. The treated mice are observed to have levels of 4âEP, 4âEPS, PC, PCS, 4â hydroxyphenylacetate, 2âhydroxyâ2(4âhydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or 3âindoxyl e similar to, equivalent to, or reduced as compared to ted mice and/or healthy subjects. CNTNAPZ'I' or Shank3'l' mice and control mice are also observed for behavioral symptoms of ASD as in Example 15.
In the open field exploration assay, untreated CNTNAPZ'I' or Shank3'l' mice display sed entries and time spent in the center of the arena, which is indicative of anxietyâlike behavior. Treated CNTNAPZ'I' or Shank3'l' mice and untreated l mice show commensurate or equivalent s of entries and time spent in the center of the arena.
In the prepulse inhibition (PPI) assay, ted CNTNAPZ'I' or Shank3'l' mice exhibit decreased PPI. Treated CNTNAPZ'I' or Shank3'l' mice and untreated control mice show normal PPI.
In the marble burying assay, untreated CNTNAPZ'I' or Shank3'l' mice display increased stereotyped marble burying compared to controls. Treated CNTNAPZ'I' or Shank3'l' mice and untreated control offspring, show normal g behavior.
In the ultrasonic zation assay, treated CNTNAPZ'I' or Shank3'l' mice and ted control mice show a normal number and duration of ultrasonic vocalizations produced in response to a social encounter.
In the threeâchamber social test, ted CNTNAPZ'I' or Shank3'l' mice exhibit deficits in both sociability and social preference. Treated Z'I' or Shank3'l' mice and untreated control mice show normal social ction.
In some experiments, an inoculant of bacteria comprising one or more of Prevotella species, Bifido bacteria species, Parabacteriodes species, (e.g., P. merdae, P. distasonis), Faecalibacterium species, (e.g., F. prausnitzii), Eubacterium species, Coprococcus species, Lactobacillus reuteri, Lactobacillus rhamnosis, Bacteroides caccae, Bacteriodes ovatus, Bacteroides fragilis, Bacteroides vulgatus, and/or Bacteroides thetaiotaomicron, or any combination thereof, is administered before, , or after administration of the sequestrant composition, and the effect of the added bacteria is determined.
Mecp2'l' or an equivalent mouse model of Rett Syndrome are evaluated for improvement in behavioral and/or gastrointestinal symptoms following treatment with an ABâ2004 preparation or other sequestering . See, e.g., Shahbazian er al. (2002), Neuron â254, which is hereby incorporated by reference in its entirety. Mecp2'l' or equivalent mice, and genetically unaltered ol) mice are either treated with ABâ2004 or other tering agent daily for 10 days or left untreated for 10 days. Mice are monitored for levels of 4âEP, 4âEPS, PC, PCS, 4âhydroxyphenylacetate, oxyâ2(4â hydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or 3âindoxyl e in blood, urine and feces. Levels of 4âEP, 4âEPS, PC, PCS, 4âhydroxyphenylacetate, 2âhydroxyâ 2(4âhydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or xyl sulfate are ed to be d in ABâ2004 treated Mecp2'l' or an equivalent mice relative to untreated Mecp2'l' or equivalent mice. The treated mice are observed to have levels of 4â EP, 4âEPS, PC, PCS, 4âhydroxyphenylacetate, 2âhydroxyâ2(4âhydroxyphenyl)acetate, homocitrulline, hydroxy indole and/or 3âindoxyl sulfate similar to, equivalent to, or reduced as compared to untreated mice and/or healthy subjects. Mecp2'l' or equivalent mice and control mice are also observed for behavioral symptoms of ASD as in Example In the open field exploration assay, untreated Mecp2'l' or lent mice display decreased entries and time spent in the center of the arena, though fecal bolus counts, grooming times, and time spent in ent areas of the field may not be affected.
Treated Mecp2â/â or an equivalent mice and untreated control mice show commensurate or equivalent amounts of entries and time spent in the center of the arena. Untreated Mecp2'l' or equivalent mice also show inertia, breathing irregularities, and hind limb clasping phenotypes not present in treated Mecp2'l' or equivalent mice or in control mice.
Mecp2'l' or equivalent mice and control mice are also tested for leaky gut symptoms by orally administering oligosaccharides of large size, such as lactulose or high MWâPEGs (1500 or 4000 kD), and/or small sugars such as mannitol, Lârhamnose, or low MWâPEG (400 kD), and/or other indigestible probes such as 51CrâEDTA. Administration of said nds occurs separately from administration of ABâ2004 or other sequestering agent. Urine is collected and monitored for the presence of such molecules, where the ce of the test molecule in the urine is matic of leaky gut.
Untreated Mecp2â/â or equivalent mice show significant amounts of lactulose, high MWâ PEGs (1500 or 4000 kD), small sugars, mannitol, Lârhamnose, low MWâPEG (400 kD), 51CrâEDTA and/or other indigestible probes in their urine after oral administration.
Treated Mecp2â/â or equivalent mice and untreated control mice show little or no lactulose, high MWâPEGs (1500 or 4000 kD), small sugars, mannitol, Lârhamnose, low MWâPEG (400 kD), 51CrâEDTA and/or other indigestible probes in their urine after oral administration.
In some experiments, an inoculant of bacteria comprising one or more of ella s, Bifido bacteria species, Parabacteriodes species, (e.g., P. merdae, P. distasonis), Faecalibacterium species, (e.g., F. itzii), Eubacterium species, Coprococcus species, Lactobacillus reuteri, Lactobacillus rhamnosis, Bacteroides caccae, Bacteriodes ovatus, Bacteroides fragilis, Bacteroides vulgatus, and/or Bacteroides thetaiotaomicron, or any combination thereof, is administered before, during, or after administration of the sequestrant composition, and the effect of the added bacteria is determined.
Example 20 We have previously generated ial strains that produce 4âethylphenol (4âEP) (the precursor to 4âEPS) and colonized mice with these strains, and have shown that intestinal production of a specific microbial metabolite is sufficient to promote anxiety and related ors in mice. Anxiety can also be induced by injection of 4âEPS.
Animals and Dosing In the present study, 3âweekâold iologically sterile (germâfree) and normally colonized specific pathogen free (SPF), C57Bl/6 mice are obtained (Jackson Labs, Bar Harbor, ME). Mice are lly divided into 4 groups: 1) specific pathogen free; 2) germâfree; 3) germâfree colonized with engineered ial strains that produce 4âEP or, alternatively, germâfree injected intravenously with 4âEPS; 4) germâfree zed with engineered bacterial strains that do not produce 4âEP. Each group is further divided into groups that are administered an ABâ2004 preparation, saline (negative control), B. fragilis (positive l), and no treatment. Each test article is administered orally, once per day or at each feeding. The test articles are administered for five weeks, followed by behavioral testing. In some groups, dosing is discontinued prior to behavioral testing, and in some groups dosing continues throughout the testing .
An ABâ2004 preparation ZO, Kureha Corporation, Japan) is given in food or by gavage, B. fragilis at 1010 cfu in 1.5% sodium bicarbonate on is administered in apple sauce plugs or by gavage, and saline is administered in food or by gavage. The ABâ2004 preparation is initially dosed at a level of 8 â lOO mg/mouse/dose and dosing is adjusted as necessary.
Behavioral testing In the elevated "plus" maze test, animals are placed on an tus having two crossed elements in the shape of a plusâsign, with one element enclosed and one element exposed. Animals having symptoms of y spend more time in the enclosed regions of the maze relative to animals without anxiety. In the t study, mice colonized with 4âEP producing bacteria and treated with ABâ2004, mice colonized with 4âEP ing bacteria and treated with B. fragilis, and mice that are not colonized by 4âEP producing bacteria (specific pathogen free, germâfree, and germâfree colonized with engineered bacterial strains that do not produce 4âEP), spend less time in the enclosed regions of the maze relative to untreated mice or mice colonized with 4âEP ing bacteria that are mockâtreated with saline, ting a reduction in anxiety symptoms due to the ABâ2004 or B. fragilis treatment.
In the dark box test, animals are placed in a box, most of which is lit, with a smaller separate dark compartment accessible to the animal. Mice showing symptoms of anxiety spend less time in the lit areas of the box relative to animals without anxiety. In the present study, mice colonized with 4âEP ing bacteria and treated with ABâ 2004, mice colonized with 4âEP producing ia and treated with B. fragilis, and mice that are not colonized by 4âEP producing bacteria (specific pathogen free, germâfree, and germâfree colonized with engineered bacterial strains that do not produce 4âEP), spend less time in the enclosed regions relative to untreated mice or mice colonized with 4âEP producing ia that are mockâtreated with saline, indicating a reduction in anxiety symptoms due to the ABâ2004 or B. fragilis treatment.
The open field ation assay is described in Example 15. In the present study, mice colonized with 4âEP producing bacteria and treated with ABâ2004, mice colonized with 4âEP producing ia and treated with B. fragilis, and mice that are not colonized by 4âEP producing bacteria (specific pathogen free, germâfree, and germâfree colonized with engineered bacterial strains that do not produce 4âEP), show more entries into the center of the arena and spend more time in the center of the arena relative to untreated mice or mice colonized with 4âEP producing bacteria that are mockâtreated with saline, indicating a reduction in y ms due to the ABâ2004 or B. fragilis treatment. havioral testing Levels of ïŹammatory markers, including ILâ6, , etc., are evaluated in tissue after sacrifice. Elevated levels of proâinïŹammatory markers are seen in mice colonized with 4âEP producing bacteria and treated with an ABâ2004 preparation, mice colonized with 4âEP producing ia and treated with B. fragilis, and mice that are not colonized by 4âEP producing bacteria (specific pathogen free, germâfree, and germâfree colonized with engineered bacterial strains that do not produce 4âEP) relative to untreated mice or mice colonized with 4âEP producing bacteria that are mockâtreated with saline, indicating a reduction in inïŹammatory responses due to the ABâ2004 or B. fragilis treatment.
Serum and urine levels of key microbial lites including 4âEP, 4âEPS, PC, PCS, 4âhydroxyphenylacetate, 2âhydroxyâ2(4âhydroxyphenyl)acetate, homocitrulline, indole pyruvate, serotonin, 3âhydroxy indole and lsulfate Will be monitored during dosing and before or tests as early indicator of sequestration. Dosing can be adjusted in order to provide additional reductions in metabolite levels. Reduced levels of anxietyâassociated metabolites are seen in mice colonized with 4âEP producing bacteria and d with an ABâ2004 preparation, mice colonized with 4âEP producing bacteria and d with B. fragilis, and mice that are not colonized by 4âEP producing bacteria (specific pathogen free, ree, and germâfree colonized with engineered bacterial strains that do not produce 4âEP) relative to untreated mice or mice colonized with 4âEP producing ia that are mockâtreated with saline, indicating a reduction in metabolite levels due to the ABâ2004 or B. fragilis treatment.
In some experiments, an inoculant of bacteria comprising one or more of Prevotella species, Bifido bacteria species, Parabacteriodes species, (e.g., P. merdae, P. distasonis), Faecalibacterium species, (e.g., F. itzii), erium species, Coprococcus species, Lactobacillus reuteri, Lactobacillus rhamnosis, Bacteroides caccae, Bacteriodes ovatus, Bacteroides vulgatus, and/or Bacteroides thetaiotaomicron, or any combination thereof, is administered rather than B. fragilis.
Example 21 The effect of ABâ2004 was studied in gnotobiotic mice that had been colonized with one or more specific bacterial s, or with human fecal matter, that had previously been characterized to produce one or more intestinal lites associated with the microbially produced lites (or hostâmodifications thereof) described herein, including 4âethylphenol (4âEP), pâcresol (PC), 3âhydroxy indole, 4âethylphenyl sulfate (4âEPS), pâcresyl sulfate (PCS), and 3âindoxyl sulfate. The effect of ABâ2004, a material that sequesters one or more intestinal lites associated with the microbially produced metabolites (or hostâmodifications thereof) bed herein, including 4â ethylphenol (4âEP), pâcresol (PC), 3âhydroxy indole, 4âethylphenyl sulfate (4âEPS), pâ cresyl sulfate (PCS), and 3âindoxyl sulfate, was investigated by formulating ABâ2004 into mouse food and administering it in parallel with a control diet that did not contain ABâ 2004 but was otherwise cal. Impact of toxic microbial lite production by the microbiota and ABâ2004 administration was ined via assessments of the levels of the toxic bacterial metabolites in samples of serum, feces and/or urine obtained from the host, impact on repetitive, social, sensory and anxietyâlike behaviors that ent core and nonâcore symptoms of autism spectrum disorders (ASD), and impact on the integrity of gastrointestinal barrier as a measure of leaky gut.
At 4 weeks of age and after weaning gnotobiotic mice were colonized with either specific bacterial strains or with human fecal matter. At the age of 5 weeks, mice were placed on a diet that contained 8% w/w ABâ2004, or an otherwise identical diet that did not contain 4. Colonization of mice was confirmed by g dilutions of fecal homogenates on solid media and assessment of bacterial strain specific markers.
Marble Burying A marble burying test was used to assess repetitive behavior, which is a core symptom of ASD. In the assay as described by Malkova er al. (Behav Immun. 26(4):607â 16 ), marbles are placed on top of bedding in a cage, a test mouse is placed in the cage, and the number of marbles buried by the mouse during the test period is measured.
Mice given control diet that were colonized with specific ial strains, or with human fecal matter, that produce toxic metabolites buried significantly more marbles than germ free gnotobiotic mice, thereby demonstrating repetitive behavior due to toxic bacterial metabolite tion by the gut iota. Administration of ABâ2004 to mice colonized with specific bacterial strains, or with human fecal matter, that produce toxic metabolites normalized this repetitive behavior in the assay. The data te that administration of materials that sequester 4âEP, PC, 3âhydroxy indole, 4âEPS, PCS, and 3âindoxyl e, can be beneficial for reducing repetitive behaviors, one of the core symptoms of ASD, in some ASD patients.
Elevated Plus Maze The elevated plus maze (EPM) test of exploratory behavior was used to assess general locomotion and yâlike behavior. Mice were d 5 minutes to explore an elevated plus maze comprised of two open arms and two closed arms that extend from a common central platform. A small raised lip around the edges of the open arms helped prevent mice from slipping off. An overhead video camera was used to record the session, and Ethovision software (Noldus Information Technology, Sacramento, CA) was used to analyze mouse movements. Time spent in closed, relatively ted portions of the maze versus time spent exploring open, relatively exposed portions of the maze is interpreted as a measurement of anxiety. Mice given control diet that were colonized with specific bacterial s, or with human fecal matter, that produce toxic metabolites spent significantly less time in the open portions of the EPM versus closed portions of the EPM than germ free gnotobiotic mice. Thereby demonstrating anxietyâlike behavior due to tion of toxic metabolites by the intestinal microbiota. Administration of ABâ2004 normalized these anxietyâlike behaviors in the assay. Anxiety is a common nonâcore symptom of ASD, and these data indicate that administration of sequestrants of 4âEP, PC, oxy indole, 4âEPS, PCS, and 3âindoxyl sulfate can be beneficial in reducing anxiety in some ASD patients.
Open Field The open field test of exploratory behavior was used to assess general locomotion and anxietyâlike behavior. For openâfield testing, mice were allowed to explore a 50 x 50âcm white Plexiglas box for 10 min. An overhead video camera was used to record the session, and Ethovision software (Noldus Information Technology, Sacramento, CA) was used to analyze the distance traveled, and the number of entries and duration of time spent in the center arena (central square, 17 x 17 cm) versus the wall area of the box. Mice given control diet that were colonized with ic ial s, or with human fecal matter, that produce toxic metabolites exhibited an anxietyâlike phenotype in this assay, spending less time within and crossing the center of the test arena, ng the wall area with r ncy and spending more time in the wall area when compared with germ free gnotobiotic mice. Administration of ABâ2004 normalized these anxietyâlike ors in the assay. Importantly, total distance moved in the open field test was similar for all groups, suggesting that differences in exploration of open versus closed parts of the field are not due to differences in the distance that the mice moved during the test. Consistent with the EPM data, these data provide additional ce that stration of materials that sequester 4âEP, PC, 3âhydroxy indole, 4âEPS, PCS, and 3âindoxyl e can be beneficial in alleviating symptoms of anxiety in ASD patients who suffer from them.
Direct Social Interaction A threeâchambered social approach test was used to measure direct social interaction. The test mouse was placed in the center chamber of three adjacent rs, with a novel object in an adjacent terminal chamber and an unfamiliar mouse in the other adjacent terminal chamber. The test mouse was habituated in the apparatus for 10 minutes prior to initiation of scoring. The test mouse was able to pass through openings from the center chamber into each of the adjacent chambers. The test was recorded by video, and the time spent by the test mouse in the chamber with the unfamiliar mouse was scored manually. A higher amount of time spent with the unfamiliar mouse is an indicator of increased sociability, while a lower amount of time spent with the unfamiliar mouse is an indicator of decreased sociability, tent with the social deficits that are a core symptom of Autism Spectrum Disorders.
In this test of social interaction, male mice colonized with specific bacterial strains, or with human fecal matter, that produce toxic lites spent significantly less time in the chamber with another mouse than male germ free gnotobiotic mice.
Administration of ABâ2004 normalized the ts in social behavior observed in the assay. These data indicate that administration of als such as 4 that sequester 4âEP, PC, 3âhydroxy indole, 4âEPS, PCS, and 3âindoxyl sulfate can be beneficial to e core symptoms of ASD, such as social deficits.
Sensory Gating Prepulse inhibition (PPI) measures the ability of an animal to inhibit its startle in response to an ic tone when it is preceded by a lowerâintensity stimulus.
Deficiencies in PPI are a e of impaired sensorimotor gating and are observed in l neurodevelopmental disorders, including autism. Mice colonized with specific bacterial strains, or with human fecal matter, that produce toxic metabolites exhibit decreased PPI response in comparison to that observed in germ free gnotobiotic mice.
Administration of ABâ2004 normalized the deficits in sensory gating observed in the assay.
Social Communication Behavior Ultrasonic vocalizations are used to measure social communication by mice, n calls of varying types and motifs are produced in different social paradigms.
Mice colonized with specific bacterial s, or with human fecal matter, that produce toxic metabolites exhibit deficits in communication, as indicated by reduced number and duration of onic vocalizations produced in se to a social encounter.
Administration of ABâ2004 normalized the deficits in social communication behavior observed in the assay.
Social Interaction Behavior The threeâchamber social test is used to e ASDârelated impairments in social interaction. Mice colonized with specific bacterial strains, or with human fecal matter, that produce toxic metabolites exhibit deficits in both sociability, or ence to interact with a novel mouse over a novel object, and social preference, or preference to interact with an unfamiliar versus a familiar mouse. stration of ABâ2004 normalized the ts in social interaction behavior observed in the assay Gastrointestinal barrier integrity Mice colonized with specific bacterial strains, or with human fecal matter, that produce toxic metabolites were also tested for leaky gut symptoms by orally administering oligosaccharides of large size, such as lactulose or high MWâPEGs (1500 or 4000 kD), and/or small sugars such as mannitol, Lârhamnose, or low MWâPEG (400 kD), and/or other indigestible probes such as DTA. Urine, blood and/or fecal samples are collected and monitored for the presence of such les, where the presence of the test molecule in the urine is symptomatic of leaky gut. Mice colonized with specific bacterial strains, or with human fecal matter, that produce toxic metabolites show significant amounts of lactulose, high MWâPEGs (1500 or 4000 kD), small sugars, mannitol, Lâ rhamnose, low MWâPEG (400 kD), SlCrâEDTA and/or other stible probes in their urine after oral administration. Administration of ABâ2004 normalized one or more of the elevated urine levels lactulose, high MWâPEGs (1500 or 4000 kD), small sugars, mannitol, nose, low MWâPEG (400 kD), SlCrâEDTA and/or other indigestible probes, indicating a correction of leaky gut.
Serum urine and feces Levels of key microbial metabolites including 4âethylphenol (4âEP), pâcresol (PC), 3âhydroxy indole, lphenyl sulfate ), pâcresyl sulfate (PCS), 3âindoxyl sulfate, indole pyruvate and/or serotonin were monitored as an indicator of sequestration.
Dosing may be adjusted in order to e additional reductions in metabolite levels. In mice zed with specific bacterial strains, or with human fecal matter, that produce toxic metabolites, treatment with 4 d levels of one or more of these target metabolites.
With respect to the use of substantially any plural and/or singular terms , those having skill in the art can translate from the plural to the singular and/or from the singular to plural as is appropriate to the context and/or application. The various singular/plural permutations can be expressly set forth herein for sake of clarity.
It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (for example, bodies of the appended claims) are generally intended as "open" terms (for example, the term "including" should be interpreted as "including but not limited to," the term "having" should be interpreted as "having at least," the term "includes" should be interpreted as "includes but is not limited to," etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims can contain usage of the introductory phrases "at least one" and "one or more" to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles "a" or "an" limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases "one or more" or "at least one" and indefinite articles such as "a" or "an" (for example, "a" and/or "an" should be interpreted to mean "at least one" or "one or more"); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a ic number of an introduced claim recitation is explicitly recited, those skilled in the art will ize that such recitation should be reted to mean at least the d number (for example, the bare recitation of "two recitations," t other modifiers, means at least two tions, or two or more recitations). Furthermore, in those instances where a convention analogous to "at least one of A, B, and C, etc." is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (for example, " a system having at least one of A, B, and C" would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention ous to "at least one of A, B, or C, etc." is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (for example, " a system having at least one of A, B, or C" would include but not be limited to s that have A alone, B alone, C alone, A and B together, A and C er, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase "A or B" will be understood to include the possibilities of "A" or "B" or "A and B." In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will ize that the disclosure is also thereby bed in terms of any individual member or subgroup of members of the h group.
As will be understood by one skilled in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subâranges and combinations of subâranges thereof. Any listed range can be easily recognized as iently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a nonâlimiting e, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as "up to,:9 6Lat least,:9 6âgreater than," "less than," and the like include the number recited and refer to ranges which can be subsequently broken down into subâ ranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1â3 es refers to groups having 1, 2, or 3 articles. Similarly, a group having 1â5 es refers to groups having 1, 2, 3, 4, or 5 articles, and so forth.
While various aspects and embodiments have been sed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being ted by the following claims.
Throughout this ication and the claims which follow, unless the context requires ise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the ion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
Claims (13)
1. Use of an activated carbon trant composition in the manufacture of a medicament for treating a oral symptom of a neurological disorder associated with autism spectrum disorder in a subject, wherein the activated carbon sequestrant composition is capable of g to at least a fraction of at least one intestinal metabolite present in the digestive tract of the subject to form a sequestrant-metabolite complex, such that the sequestrant-metabolite complex is eliminated from the digestive tract; wherein the at least one intestinal metabolite is 4-ethylphenol and the behavioral m is selected from the group consisting of repetitive behaviors, stereotyped behaviors, obsessive ors, deficits in social communication, and clinical irritability; wherein the activated carbon sequestrant composition comprises a multiplicity of biocompatible particles which are non-absorbable by the digestive tract of the subject.
2. The use of claim 1 wherein: the neurological disorder is autism spectrum disorder and the behavioral symptom is selected from the group consisting of tive behaviors, stereotyped behaviors, and ts in social communication.
3. The use of claim 1 or 2 wherein: the subject does not have clinical anxiety or an anxiety disorder.
4. The use of any one of claims 1-3 n: the subject does not have chronic kidney disease.
5. The use of any one of claims 1-4 wherein: the activated carbon sequestrant composition is capable of binding to at least a portion of an additional intestinal metabolite present in the digestive tract of the subject to form a sequestrant-metabolite complex, such that the sequestrant-metabolite complex is eliminated from the digestive tract, wherein the additional metabolite is selected from the group consisting of: 4-ethylphenylsulfate (4-EPS), ol (PC), p-cresyl sulfate (PCS), 3-hydroxy indole, and 3-indoxyl sulfate.
6. The use of any one of claims 1-5 wherein: the activated carbon trant composition comprises an AB-2004 preparation comprising spherical activated carbon particles having a minimum average specific surface area determined by the Brunauer-Emmett-Teller (BET) method of at least 500 m2/g and a m average ic surface area determined by the Brunauer-Emmett- Teller (BET) method less than 4000 m2/g.
7. The use of claim 1 or 6 wherein: the activated carbon sequestrant composition comprises an AB-2004 ation comprising spherical ted carbon particles having a minimum average particle diameter of at least 0.005 mm and a maximum e particle diameter of less than 1.5
8. The use of any one of claims 1-7, wherein the intestinal metabolite levels of the subject are intended to be monitored during the course of treatment.
9. The use of any one of claims 1-8, wherein s in the oral symptom of the t are intended to be monitored during the course of treatment.
10. The use of any one of claims 1-8, wherein the activated carbon sequestrant composition is intended for administration following appearance of the behavioral symptom of the neurological disorder.
11. The use of any one of claims 1-8, wherein administration of the medicament is intended to be repeated as necessary to maintain reduced levels of intestinal metabolites relative to levels identified prior to first administration of the medicament.
12. The use of any one of claims 1-11 wherein: the medicament is intended for administration of the activated carbon sequestrant composition in an amount of from 5 mg/kg to 500 mg/kg of body weight per day.
13. The use of any one of claims 1-12, wherein the medicament is intended for administration to the t of an therapeutically effective amount of the activated carbon sequestrant composition of from 35 mg to 35 g per day. 4EPS ïŹn Bi-comnimd Mice 20000; urine 15oeef 4EPS 1eaoaĂ© ngimL 5003f lic Potentiai of Microbiota
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762480039P | 2017-03-31 | 2017-03-31 | |
US62/480,039 | 2017-03-31 | ||
PCT/US2018/025607 WO2018183986A1 (en) | 2017-03-31 | 2018-03-31 | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ758692A NZ758692A (en) | 2022-03-25 |
NZ758692B2 true NZ758692B2 (en) | 2022-06-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021206871B2 (en) | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders | |
KR102441934B1 (en) | Porous carbon particles for use in the treatment or prevention of liver disease | |
EP3465212A1 (en) | Regulate gut microbiota to treat neurodegenerative disorders | |
TWI243678B (en) | A pharmaceutical composition for the treatment and/or prophylaxis of conditions characterized by altered bowel function and/or visceral pain in human or non-human mammals | |
KR20080081186A (en) | Novel lactobacillus strains and their use against helicobacter pylori | |
JP2019189616A (en) | Pharmaceutical compositions containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid level by modifying intestinal microbiota | |
JP2021507945A (en) | Compositions and treatments for neuropathy, including dementia | |
BR112013028496B1 (en) | BACTERIAL COMPOSITION IN THE TREATMENT OF HYPERCOLESTEROLEMIA | |
PT2415475E (en) | Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum | |
CN114099696B (en) | Nano-selenium sodium alginate composite gel and preparation method and application thereof | |
CN114615971A (en) | Compositions comprising bacterial strains | |
NZ758692B2 (en) | Gut-selective sequestering agents for the treatment and prevention of autism and related disorders | |
JP2022552005A (en) | Compositions and methods for delivering bacterial metabolites to a subject | |
NZ785988A (en) | Gut-selective sequestering agents for the treatment and prevention of autism and | |
EP2945626B1 (en) | Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy | |
Xia et al. | Ulcerative colitis alleviation of colon-specific delivered rhamnolipid/fullerene nanocomposites via dual modulation in oxidative stress and intestinal microbiome | |
Zhang et al. | Research progress of microbiota-gut-brain axis in parkinson's disease | |
WO2023154966A1 (en) | Compositions and methods for sequestering metabolites in the gastrointestinal tract | |
NĂĄpoles-Medina et al. | Oral Administration of Lactobacillus Inhibits the Permeability of Blood-Brain and Gut Barriers in a Parkinsonism Model | |
Negm | MASTERARBEIT/MASTERâS THESIS | |
WO2022010352A1 (en) | 5-hydroxyindole and analogs thereof as stimulants of gut motility | |
CN117898436A (en) | Composition for preventing parkinsonism and application thereof |